https://trial.medpath.com/news/atezolizumab-shows-mixed-results-in-advanced-endometrial-cancer-trial-benefits-dmmr-patients 2025-10-19T21:28:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/atezolizumab-shows-mixed-results-in-advanced-endometrial-cancer-trial-benefits-dmmr-patients 2025-10-19T21:28:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-second-complete-response-letter-to-xbrane-s-ranibizumab-biosimilar-application 2025-10-19T21:26:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-second-complete-response-letter-to-xbrane-s-ranibizumab-biosimilar-application 2025-10-19T21:26:01+00:00 hourly 0.9 https://trial.medpath.com/news/dream3r-phase-3-trial-shows-promise-but-inconclusive-results-for-durvalumab-in-advanced-pleural-mesothelioma 2025-10-19T21:24:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dream3r-phase-3-trial-shows-promise-but-inconclusive-results-for-durvalumab-in-advanced-pleural-mesothelioma 2025-10-19T21:24:51+00:00 hourly 0.9 https://trial.medpath.com/news/ioncologi-secures-key-patent-for-rna-based-cancer-immunotherapy-as-studies-link-covid-19-mrna-vaccines-to-enhanced-checkpoint-inhibitor-response 2025-10-19T21:24:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ioncologi-secures-key-patent-for-rna-based-cancer-immunotherapy-as-studies-link-covid-19-mrna-vaccines-to-enhanced-checkpoint-inhibitor-response 2025-10-19T21:24:48+00:00 hourly 0.9 https://trial.medpath.com/news/mckesson-expands-oncology-distribution-network-with-lymphir-and-phyrago-partnerships 2025-10-19T21:23:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mckesson-expands-oncology-distribution-network-with-lymphir-and-phyrago-partnerships 2025-10-19T21:23:37+00:00 hourly 0.9 https://trial.medpath.com/news/moderna-s-mrna-flu-vaccines-show-promising-efficacy-and-safety-data-at-idweek-2025 2025-10-19T17:20:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moderna-s-mrna-flu-vaccines-show-promising-efficacy-and-safety-data-at-idweek-2025 2025-10-19T17:20:11+00:00 hourly 0.9 https://trial.medpath.com/news/daiichi-sankyo-s-ds-3939-shows-promising-early-results-in-advanced-solid-tumors-phase-1-2-trial 2025-10-19T17:17:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/daiichi-sankyo-s-ds-3939-shows-promising-early-results-in-advanced-solid-tumors-phase-1-2-trial 2025-10-19T17:17:48+00:00 hourly 0.9 https://trial.medpath.com/news/avelumab-shows-modest-activity-in-advanced-penile-cancer-but-fails-to-deliver-transformative-survival-benefits 2025-10-19T17:16:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avelumab-shows-modest-activity-in-advanced-penile-cancer-but-fails-to-deliver-transformative-survival-benefits 2025-10-19T17:16:58+00:00 hourly 0.9 https://trial.medpath.com/news/wuhan-yzy-biopharma-s-m701-shows-superior-efficacy-over-cisplatin-in-phase-ii-trial-for-malignant-pleural-effusion 2025-10-19T17:16:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wuhan-yzy-biopharma-s-m701-shows-superior-efficacy-over-cisplatin-in-phase-ii-trial-for-malignant-pleural-effusion 2025-10-19T17:16:56+00:00 hourly 0.9 https://trial.medpath.com/news/capivasertib-shows-significant-survival-benefit-in-pten-deficient-metastatic-prostate-cancer 2025-10-19T17:15:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/capivasertib-shows-significant-survival-benefit-in-pten-deficient-metastatic-prostate-cancer 2025-10-19T17:15:54+00:00 hourly 0.9 https://trial.medpath.com/news/rapt-therapeutics-prepares-to-release-phase-2-data-for-rpt904-in-chronic-spontaneous-urticaria 2025-10-19T17:15:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rapt-therapeutics-prepares-to-release-phase-2-data-for-rpt904-in-chronic-spontaneous-urticaria 2025-10-19T17:15:47+00:00 hourly 0.9 https://trial.medpath.com/news/j-j-s-rybrevant-shows-45-response-rate-in-head-and-neck-cancer-doubling-standard-of-care 2025-10-19T17:15:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/j-j-s-rybrevant-shows-45-response-rate-in-head-and-neck-cancer-doubling-standard-of-care 2025-10-19T17:15:35+00:00 hourly 0.9 https://trial.medpath.com/news/subcutaneous-amivantamab-shows-45-response-rate-in-recurrent-head-and-neck-cancer 2025-10-19T17:15:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/subcutaneous-amivantamab-shows-45-response-rate-in-recurrent-head-and-neck-cancer 2025-10-19T17:15:27+00:00 hourly 0.9 https://trial.medpath.com/news/therapeutic-cancer-vaccines-show-promise-for-pancreatic-cancer-treatment-despite-immunosuppressive-challenges 2025-10-19T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/therapeutic-cancer-vaccines-show-promise-for-pancreatic-cancer-treatment-despite-immunosuppressive-challenges 2025-10-19T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/nanomaterial-enhanced-mri-reveals-novel-biomarkers-for-hepatocellular-carcinoma-diagnosis-and-therapy 2025-10-19T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nanomaterial-enhanced-mri-reveals-novel-biomarkers-for-hepatocellular-carcinoma-diagnosis-and-therapy 2025-10-19T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-s-braftovi-plus-mektovi-achieves-nearly-four-year-survival-in-braf-mutant-lung-cancer 2025-10-19T14:50:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pfizer-s-braftovi-plus-mektovi-achieves-nearly-four-year-survival-in-braf-mutant-lung-cancer 2025-10-19T14:50:04+00:00 hourly 0.9 https://trial.medpath.com/news/mrna-covid-19-vaccines-show-promise-in-enhancing-cancer-immunotherapy-survival-rates 2025-10-19T14:48:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mrna-covid-19-vaccines-show-promise-in-enhancing-cancer-immunotherapy-survival-rates 2025-10-19T14:48:36+00:00 hourly 0.9 https://trial.medpath.com/news/rsv-immunization-safe-for-infants-regardless-of-maternal-vaccination-status-new-study-shows 2025-10-19T09:19:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rsv-immunization-safe-for-infants-regardless-of-maternal-vaccination-status-new-study-shows 2025-10-19T09:19:06+00:00 hourly 0.9 https://trial.medpath.com/news/carsgen-s-allogeneic-bcma-car-t-therapy-ct0596-shows-promising-results-in-rare-primary-plasma-cell-leukemia 2025-10-19T09:19:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/carsgen-s-allogeneic-bcma-car-t-therapy-ct0596-shows-promising-results-in-rare-primary-plasma-cell-leukemia 2025-10-19T09:19:03+00:00 hourly 0.9 https://trial.medpath.com/news/leap-014-trial-shows-lenvatinib-triple-combination-fails-to-improve-survival-in-metastatic-esophageal-cancer 2025-10-19T01:39:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/leap-014-trial-shows-lenvatinib-triple-combination-fails-to-improve-survival-in-metastatic-esophageal-cancer 2025-10-19T01:39:50+00:00 hourly 0.9 https://trial.medpath.com/news/phase-3-trial-demonstrates-safety-and-efficacy-of-epithelium-on-corneal-cross-linking-for-keratoconus-treatment 2025-10-19T01:39:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-3-trial-demonstrates-safety-and-efficacy-of-epithelium-on-corneal-cross-linking-for-keratoconus-treatment 2025-10-19T01:39:16+00:00 hourly 0.9 https://trial.medpath.com/news/cork-biotech-arraypatch-wins-eur800k-seedcorn-award-for-revolutionary-microneedle-drug-delivery-technology 2025-10-19T01:37:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cork-biotech-arraypatch-wins-eur800k-seedcorn-award-for-revolutionary-microneedle-drug-delivery-technology 2025-10-19T01:37:17+00:00 hourly 0.9 https://trial.medpath.com/news/cadonilimab-plus-chemotherapy-demonstrates-sustained-survival-benefit-in-advanced-gastric-cancer-final-analysis 2025-10-19T01:35:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cadonilimab-plus-chemotherapy-demonstrates-sustained-survival-benefit-in-advanced-gastric-cancer-final-analysis 2025-10-19T01:35:17+00:00 hourly 0.9 https://trial.medpath.com/news/aurion-biotech-s-aurn001-cell-therapy-achieves-all-endpoints-in-phase-1-2-trial-for-corneal-endothelial-disease 2025-10-18T21:26:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aurion-biotech-s-aurn001-cell-therapy-achieves-all-endpoints-in-phase-1-2-trial-for-corneal-endothelial-disease 2025-10-18T21:26:32+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-eyes-full-acquisition-of-protagonist-therapeutics-following-successful-icotrokinra-partnership 2025-10-18T21:25:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/johnson-johnson-eyes-full-acquisition-of-protagonist-therapeutics-following-successful-icotrokinra-partnership 2025-10-18T21:25:24+00:00 hourly 0.9 https://trial.medpath.com/news/il33-st2-axis-emerges-as-predictive-biomarker-for-anti-pd1-therapy-in-advanced-gastric-cancer 2025-10-18T21:23:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/il33-st2-axis-emerges-as-predictive-biomarker-for-anti-pd1-therapy-in-advanced-gastric-cancer 2025-10-18T21:23:03+00:00 hourly 0.9 https://trial.medpath.com/news/taysha-gene-therapies-faces-mounting-financial-pressure-amid-leadership-changes-and-operational-challenges 2025-10-18T21:22:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/taysha-gene-therapies-faces-mounting-financial-pressure-amid-leadership-changes-and-operational-challenges 2025-10-18T21:22:58+00:00 hourly 0.9 https://trial.medpath.com/news/xtr008-achieves-dramatic-progression-free-survival-benefit-in-advanced-gastroenteropancreatic-neuroendocrine-tumors 2025-10-18T21:21:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/xtr008-achieves-dramatic-progression-free-survival-benefit-in-advanced-gastroenteropancreatic-neuroendocrine-tumors 2025-10-18T21:21:09+00:00 hourly 0.9 https://trial.medpath.com/news/invikafusp-alfa-shows-promise-in-checkpoint-inhibitor-resistant-solid-tumors-with-high-disease-control-rates 2025-10-18T21:20:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/invikafusp-alfa-shows-promise-in-checkpoint-inhibitor-resistant-solid-tumors-with-high-disease-control-rates 2025-10-18T21:20:42+00:00 hourly 0.9 https://trial.medpath.com/news/novel-monoclonal-antibody-mam01-demonstrates-complete-protection-against-malaria-in-phase-1-trial 2025-10-18T17:23:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-monoclonal-antibody-mam01-demonstrates-complete-protection-against-malaria-in-phase-1-trial 2025-10-18T17:23:03+00:00 hourly 0.9 https://trial.medpath.com/news/y-ora-vision-launches-with-novel-migs-device-for-glaucoma-treatment-following-seri-eyexora-licensing-deal 2025-10-18T17:22:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/y-ora-vision-launches-with-novel-migs-device-for-glaucoma-treatment-following-seri-eyexora-licensing-deal 2025-10-18T17:22:46+00:00 hourly 0.9 https://trial.medpath.com/news/moderna-advances-mrna-4359-as-late-stage-oncology-asset-with-new-melanoma-data 2025-10-18T17:22:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moderna-advances-mrna-4359-as-late-stage-oncology-asset-with-new-melanoma-data 2025-10-18T17:22:37+00:00 hourly 0.9 https://trial.medpath.com/news/scg142-demonstrates-100-disease-control-rate-in-first-in-human-trial-for-hpv-associated-cancers 2025-10-18T17:20:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scg142-demonstrates-100-disease-control-rate-in-first-in-human-trial-for-hpv-associated-cancers 2025-10-18T17:20:33+00:00 hourly 0.9 https://trial.medpath.com/news/keytruda-plus-lenvima-shows-durable-5-year-survival-benefit-in-advanced-endometrial-cancer 2025-10-18T17:19:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/keytruda-plus-lenvima-shows-durable-5-year-survival-benefit-in-advanced-endometrial-cancer 2025-10-18T17:19:17+00:00 hourly 0.9 https://trial.medpath.com/news/vimseltinib-shows-durable-two-year-efficacy-in-tenosynovial-giant-cell-tumor-phase-3-trial 2025-10-18T17:18:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vimseltinib-shows-durable-two-year-efficacy-in-tenosynovial-giant-cell-tumor-phase-3-trial 2025-10-18T17:18:28+00:00 hourly 0.9 https://trial.medpath.com/news/india-develops-first-indigenous-antibiotic-nafithromycin-for-resistant-respiratory-infections 2025-10-18T17:18:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/india-develops-first-indigenous-antibiotic-nafithromycin-for-resistant-respiratory-infections 2025-10-18T17:18:10+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-iron-based-contrast-agent-for-brain-mri-imaging 2025-10-18T17:16:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-first-iron-based-contrast-agent-for-brain-mri-imaging 2025-10-18T17:16:40+00:00 hourly 0.9 https://trial.medpath.com/news/topical-vaginal-drug-therapy-shows-promise-as-novel-cervical-cancer-treatment-approach 2025-10-18T17:16:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/topical-vaginal-drug-therapy-shows-promise-as-novel-cervical-cancer-treatment-approach 2025-10-18T17:16:37+00:00 hourly 0.9 https://trial.medpath.com/news/celcuity-reports-promising-phase-1-results-for-gedatolisib-darolutamide-combination-in-metastatic-prostate-cancer 2025-10-18T13:41:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/celcuity-reports-promising-phase-1-results-for-gedatolisib-darolutamide-combination-in-metastatic-prostate-cancer 2025-10-18T13:41:14+00:00 hourly 0.9 https://trial.medpath.com/news/precede-biosciences-unveils-liquid-biopsy-platform-for-small-cell-lung-cancer-target-expression-at-esmo-2025 2025-10-18T13:40:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/precede-biosciences-unveils-liquid-biopsy-platform-for-small-cell-lung-cancer-target-expression-at-esmo-2025 2025-10-18T13:40:14+00:00 hourly 0.9 https://trial.medpath.com/news/salubris-biotherapeutics-reports-promising-phase-1-results-for-5t4-targeted-adc-jk06-in-advanced-solid-tumors 2025-10-18T13:40:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/salubris-biotherapeutics-reports-promising-phase-1-results-for-5t4-targeted-adc-jk06-in-advanced-solid-tumors 2025-10-18T13:40:11+00:00 hourly 0.9 https://trial.medpath.com/news/nurix-therapeutics-nx-1607-shows-49-3-disease-control-rate-in-first-in-class-cbl-b-inhibitor-trial 2025-10-18T13:39:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nurix-therapeutics-nx-1607-shows-49-3-disease-control-rate-in-first-in-class-cbl-b-inhibitor-trial 2025-10-18T13:39:54+00:00 hourly 0.9 https://trial.medpath.com/news/pherflot-trial-achieves-48-complete-response-rate-in-her2-positive-gastric-cancer 2025-10-18T13:39:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pherflot-trial-achieves-48-complete-response-rate-in-her2-positive-gastric-cancer 2025-10-18T13:39:05+00:00 hourly 0.9 https://trial.medpath.com/news/roche-acquires-hansoh-s-cdh17-targeting-adc-hs-20110-in-1-45-billion-deal 2025-10-18T13:37:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-acquires-hansoh-s-cdh17-targeting-adc-hs-20110-in-1-45-billion-deal 2025-10-18T13:37:56+00:00 hourly 0.9 https://trial.medpath.com/news/doxypep-shows-mixed-results-against-stis-as-resistance-concerns-mount-in-clinical-studies 2025-10-18T10:33:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/doxypep-shows-mixed-results-against-stis-as-resistance-concerns-mount-in-clinical-studies 2025-10-18T10:33:00+00:00 hourly 0.9 https://trial.medpath.com/news/uspto-director-takes-direct-control-of-patent-challenge-reviews-potentially-strengthening-patent-protection 2025-10-18T09:40:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uspto-director-takes-direct-control-of-patent-challenge-reviews-potentially-strengthening-patent-protection 2025-10-18T09:40:07+00:00 hourly 0.9 https://trial.medpath.com/news/lenvatinib-everolimus-combination-outperforms-cabozantinib-in-second-line-kidney-cancer-treatment 2025-10-18T09:35:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lenvatinib-everolimus-combination-outperforms-cabozantinib-in-second-line-kidney-cancer-treatment 2025-10-18T09:35:29+00:00 hourly 0.9 https://trial.medpath.com/news/rituximab-shows-promise-for-treatment-resistant-hypersensitivity-pneumonitis-in-new-study 2025-10-18T00:48:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rituximab-shows-promise-for-treatment-resistant-hypersensitivity-pneumonitis-in-new-study 2025-10-18T00:48:48+00:00 hourly 0.9 https://trial.medpath.com/news/ponsegromab-shows-sustained-weight-gain-in-cancer-cachexia-patients-over-64-week-extension-study 2025-10-18T00:48:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ponsegromab-shows-sustained-weight-gain-in-cancer-cachexia-patients-over-64-week-extension-study 2025-10-18T00:48:06+00:00 hourly 0.9 https://trial.medpath.com/news/cardiol-therapeutics-secures-11m-funding-to-advance-heart-disease-pipeline-following-breakthrough-archer-trial-results 2025-10-18T00:45:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cardiol-therapeutics-secures-11m-funding-to-advance-heart-disease-pipeline-following-breakthrough-archer-trial-results 2025-10-18T00:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/major-pharma-consortium-develops-digital-endpoint-for-atopic-dermatitis-clinical-trials 2025-10-18T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/major-pharma-consortium-develops-digital-endpoint-for-atopic-dermatitis-clinical-trials 2025-10-18T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/rutgers-scientists-identify-mitochondrial-mechanism-behind-venetoclax-resistance-in-acute-myeloid-leukemia 2025-10-17T22:14:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rutgers-scientists-identify-mitochondrial-mechanism-behind-venetoclax-resistance-in-acute-myeloid-leukemia 2025-10-17T22:14:37+00:00 hourly 0.9 https://trial.medpath.com/news/silver-creek-pharmaceuticals-receives-fda-fast-track-designation-for-novel-stroke-therapy-scp776 2025-10-17T22:10:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/silver-creek-pharmaceuticals-receives-fda-fast-track-designation-for-novel-stroke-therapy-scp776 2025-10-17T22:10:22+00:00 hourly 0.9 https://trial.medpath.com/news/imunon-s-dna-vaccine-shows-superior-durability-over-mrna-vaccines-in-phase-1-covid-19-trial 2025-10-17T22:09:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/imunon-s-dna-vaccine-shows-superior-durability-over-mrna-vaccines-in-phase-1-covid-19-trial 2025-10-17T22:09:26+00:00 hourly 0.9 https://trial.medpath.com/news/zongertinib-shows-77-response-rate-in-first-line-treatment-of-her2-mutant-lung-cancer 2025-10-17T22:05:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zongertinib-shows-77-response-rate-in-first-line-treatment-of-her2-mutant-lung-cancer 2025-10-17T22:05:01+00:00 hourly 0.9 https://trial.medpath.com/news/serum-cd80-emerges-as-predictive-biomarker-for-neoadjuvant-immunotherapy-response-in-esophageal-cancer 2025-10-17T22:03:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/serum-cd80-emerges-as-predictive-biomarker-for-neoadjuvant-immunotherapy-response-in-esophageal-cancer 2025-10-17T22:03:42+00:00 hourly 0.9 https://trial.medpath.com/news/comprehensive-analysis-of-checkpoint-inhibitor-pneumonitis-reveals-key-risk-factors-and-management-patterns-across-25-nivolumab-trials 2025-10-17T21:57:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/comprehensive-analysis-of-checkpoint-inhibitor-pneumonitis-reveals-key-risk-factors-and-management-patterns-across-25-nivolumab-trials 2025-10-17T21:57:41+00:00 hourly 0.9 https://trial.medpath.com/news/abvc-biopharma-reports-1-27-million-q3-licensing-revenue-as-cns-pipeline-advances-toward-phase-iii 2025-10-17T17:29:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abvc-biopharma-reports-1-27-million-q3-licensing-revenue-as-cns-pipeline-advances-toward-phase-iii 2025-10-17T17:29:48+00:00 hourly 0.9 https://trial.medpath.com/news/disc-medicine-to-present-phase-2-rally-mf-trial-data-for-disc-0974-in-myelofibrosis-associated-anemia-at-ash-2025 2025-10-17T17:28:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/disc-medicine-to-present-phase-2-rally-mf-trial-data-for-disc-0974-in-myelofibrosis-associated-anemia-at-ash-2025 2025-10-17T17:28:53+00:00 hourly 0.9 https://trial.medpath.com/news/dovato-demonstrates-non-inferior-efficacy-to-biktarvy-with-significantly-less-weight-gain-in-96-week-hiv-treatment-study 2025-10-17T17:28:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dovato-demonstrates-non-inferior-efficacy-to-biktarvy-with-significantly-less-weight-gain-in-96-week-hiv-treatment-study 2025-10-17T17:28:12+00:00 hourly 0.9 https://trial.medpath.com/news/corvus-pharmaceuticals-reports-promising-interim-data-for-ciforadenant-triple-therapy-in-metastatic-renal-cell-cancer 2025-10-17T17:27:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/corvus-pharmaceuticals-reports-promising-interim-data-for-ciforadenant-triple-therapy-in-metastatic-renal-cell-cancer 2025-10-17T17:27:40+00:00 hourly 0.9 https://trial.medpath.com/news/artiva-biotherapeutics-receives-fda-fast-track-designation-for-allonk-cell-therapy-in-refractory-rheumatoid-arthritis 2025-10-17T17:23:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/artiva-biotherapeutics-receives-fda-fast-track-designation-for-allonk-cell-therapy-in-refractory-rheumatoid-arthritis 2025-10-17T17:23:58+00:00 hourly 0.9 https://trial.medpath.com/news/phase-3-alban-trial-shows-atezolizumab-plus-bcg-fails-to-improve-outcomes-in-high-risk-bladder-cancer 2025-10-17T17:23:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-3-alban-trial-shows-atezolizumab-plus-bcg-fails-to-improve-outcomes-in-high-risk-bladder-cancer 2025-10-17T17:23:37+00:00 hourly 0.9 https://trial.medpath.com/news/itm-to-present-phase-3-compete-trial-subgroup-analyses-at-nanets-2025-highlighting-177lu-edotreotide-success-in-gep-nets 2025-10-17T17:23:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/itm-to-present-phase-3-compete-trial-subgroup-analyses-at-nanets-2025-highlighting-177lu-edotreotide-success-in-gep-nets 2025-10-17T17:23:35+00:00 hourly 0.9 https://trial.medpath.com/news/ucl-scientists-engineer-gdt-cells-to-target-chemotherapy-resistant-bowel-cancer 2025-10-17T17:22:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ucl-scientists-engineer-gdt-cells-to-target-chemotherapy-resistant-bowel-cancer 2025-10-17T17:22:50+00:00 hourly 0.9 https://trial.medpath.com/news/regeneron-s-gene-therapy-shows-remarkable-success-in-treating-inherited-deafness 2025-10-17T17:22:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regeneron-s-gene-therapy-shows-remarkable-success-in-treating-inherited-deafness 2025-10-17T17:22:31+00:00 hourly 0.9 https://trial.medpath.com/news/pimicotinib-shows-deepening-tumor-responses-in-tgct-patients-with-76-2-response-rate-at-extended-follow-up 2025-10-17T17:21:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pimicotinib-shows-deepening-tumor-responses-in-tgct-patients-with-76-2-response-rate-at-extended-follow-up 2025-10-17T17:21:47+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-orphan-drug-designation-to-kiniksa-s-kpl-387-for-pericarditis-treatment 2025-10-17T17:20:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-orphan-drug-designation-to-kiniksa-s-kpl-387-for-pericarditis-treatment 2025-10-17T17:20:00+00:00 hourly 0.9 https://trial.medpath.com/news/multitude-therapeutics-reports-promising-phase-i-ii-results-for-cd44v9-directed-adc-amt-116-in-advanced-solid-tumors 2025-10-17T17:18:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/multitude-therapeutics-reports-promising-phase-i-ii-results-for-cd44v9-directed-adc-amt-116-in-advanced-solid-tumors 2025-10-17T17:18:02+00:00 hourly 0.9 https://trial.medpath.com/news/pin1-inhibitors-demonstrate-novel-antiviral-mechanism-against-hsv-1-by-trapping-virus-in-cell-nucleus 2025-10-17T17:16:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pin1-inhibitors-demonstrate-novel-antiviral-mechanism-against-hsv-1-by-trapping-virus-in-cell-nucleus 2025-10-17T17:16:35+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-sir-spheres-y-90-resin-microspheres-for-unresectable-hepatocellular-carcinoma 2025-10-17T17:15:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-sir-spheres-y-90-resin-microspheres-for-unresectable-hepatocellular-carcinoma 2025-10-17T17:15:53+00:00 hourly 0.9 https://trial.medpath.com/news/tonix-pharmaceuticals-reports-promising-preclinical-data-for-tnx-801-mpox-vaccine-at-world-vaccine-congress 2025-10-17T17:15:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tonix-pharmaceuticals-reports-promising-preclinical-data-for-tnx-801-mpox-vaccine-at-world-vaccine-congress 2025-10-17T17:15:47+00:00 hourly 0.9 https://trial.medpath.com/news/boston-scientific-to-acquire-nalu-medical-for-533-million-expanding-peripheral-nerve-stimulation-portfolio 2025-10-17T17:15:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/boston-scientific-to-acquire-nalu-medical-for-533-million-expanding-peripheral-nerve-stimulation-portfolio 2025-10-17T17:15:13+00:00 hourly 0.9 https://trial.medpath.com/news/european-regulators-reject-sanofi-s-rezurock-for-chronic-graft-vs-host-disease-treatment 2025-10-17T14:02:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/european-regulators-reject-sanofi-s-rezurock-for-chronic-graft-vs-host-disease-treatment 2025-10-17T14:02:33+00:00 hourly 0.9 https://trial.medpath.com/news/parabilis-medicines-achieves-first-ever-clinical-success-targeting-undruggable-b-catenin-tcf-interaction-with-fog-001 2025-10-17T13:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/parabilis-medicines-achieves-first-ever-clinical-success-targeting-undruggable-b-catenin-tcf-interaction-with-fog-001 2025-10-17T13:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-expanded-pediatric-indications-for-yuflyma-biosimilar-extending-treatment-options-for-adolescent-hidradenitis-suppurativa-and-pediatric-uveitis 2025-10-17T13:52:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-expanded-pediatric-indications-for-yuflyma-biosimilar-extending-treatment-options-for-adolescent-hidradenitis-suppurativa-and-pediatric-uveitis 2025-10-17T13:52:33+00:00 hourly 0.9 https://trial.medpath.com/news/ema-rejects-extended-dosing-regimen-for-fabry-disease-treatment-elfabrio 2025-10-17T13:50:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-rejects-extended-dosing-regimen-for-fabry-disease-treatment-elfabrio 2025-10-17T13:50:19+00:00 hourly 0.9 https://trial.medpath.com/news/fda-mandates-dpyd-genetic-testing-before-capecitabine-chemotherapy-to-prevent-fatal-toxicity 2025-10-17T09:19:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-mandates-dpyd-genetic-testing-before-capecitabine-chemotherapy-to-prevent-fatal-toxicity 2025-10-17T09:19:26+00:00 hourly 0.9 https://trial.medpath.com/news/cstone-pharmaceuticals-receives-positive-ema-opinion-for-sugemalimab-in-stage-iii-nsclc 2025-10-17T09:17:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cstone-pharmaceuticals-receives-positive-ema-opinion-for-sugemalimab-in-stage-iii-nsclc 2025-10-17T09:17:06+00:00 hourly 0.9 https://trial.medpath.com/news/nice-approves-long-acting-hiv-prevention-injection-for-england-and-wales 2025-10-17T09:16:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nice-approves-long-acting-hiv-prevention-injection-for-england-and-wales 2025-10-17T09:16:09+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-s-rinvoq-becomes-first-oral-jak-inhibitor-approved-for-giant-cell-arteritis-as-novartis-cosentyx-fails-phase-iii-trial 2025-10-17T05:16:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbvie-s-rinvoq-becomes-first-oral-jak-inhibitor-approved-for-giant-cell-arteritis-as-novartis-cosentyx-fails-phase-iii-trial 2025-10-17T05:16:54+00:00 hourly 0.9 https://trial.medpath.com/news/dompe-receives-fda-priority-voucher-for-intranasal-ngf-therapy-targeting-naion-vision-loss 2025-10-17T05:16:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dompe-receives-fda-priority-voucher-for-intranasal-ngf-therapy-targeting-naion-vision-loss 2025-10-17T05:16:42+00:00 hourly 0.9 https://trial.medpath.com/news/samsung-invests-110-million-in-grail-to-bring-multi-cancer-blood-test-to-asia 2025-10-17T05:16:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/samsung-invests-110-million-in-grail-to-bring-multi-cancer-blood-test-to-asia 2025-10-17T05:16:30+00:00 hourly 0.9 https://trial.medpath.com/news/i-mab-announces-strategic-transformation-to-novabridge-biosciences-with-hong-kong-ipo-plans-and-vis-101-acquisition 2025-10-17T01:21:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/i-mab-announces-strategic-transformation-to-novabridge-biosciences-with-hong-kong-ipo-plans-and-vis-101-acquisition 2025-10-17T01:21:43+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-second-generic-mifepristone-despite-political-opposition 2025-10-17T01:20:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-second-generic-mifepristone-despite-political-opposition 2025-10-17T01:20:55+00:00 hourly 0.9 https://trial.medpath.com/news/trump-administration-secures-deal-with-emd-serono-to-cut-fertility-drug-prices-by-up-to-84 2025-10-17T01:18:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trump-administration-secures-deal-with-emd-serono-to-cut-fertility-drug-prices-by-up-to-84 2025-10-17T01:18:51+00:00 hourly 0.9 https://trial.medpath.com/news/artiva-s-allonk-receives-fda-fast-track-designation-for-refractory-rheumatoid-arthritis 2025-10-17T01:18:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/artiva-s-allonk-receives-fda-fast-track-designation-for-refractory-rheumatoid-arthritis 2025-10-17T01:18:14+00:00 hourly 0.9 https://trial.medpath.com/news/large-french-study-confirms-mrna-covid-19-vaccines-safe-during-early-pregnancy-no-increased-birth-defect-risk 2025-10-17T01:18:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/large-french-study-confirms-mrna-covid-19-vaccines-safe-during-early-pregnancy-no-increased-birth-defect-risk 2025-10-17T01:18:04+00:00 hourly 0.9 https://trial.medpath.com/news/immunai-and-astrazeneca-expand-partnership-with-85m-ibd-target-discovery-deal 2025-10-17T01:17:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunai-and-astrazeneca-expand-partnership-with-85m-ibd-target-discovery-deal 2025-10-17T01:17:42+00:00 hourly 0.9 https://trial.medpath.com/news/vanderbilt-researcher-develops-ai-framework-to-overcome-drug-discovery-generalization-challenge 2025-10-17T01:17:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vanderbilt-researcher-develops-ai-framework-to-overcome-drug-discovery-generalization-challenge 2025-10-17T01:17:08+00:00 hourly 0.9 https://trial.medpath.com/news/dna-based-sensor-enables-5-minute-drug-monitoring-from-single-blood-drop-at-home 2025-10-17T01:16:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dna-based-sensor-enables-5-minute-drug-monitoring-from-single-blood-drop-at-home 2025-10-17T01:16:37+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-breakthrough-therapy-designation-to-bpl-003-nasal-spray-for-treatment-resistant-depression 2025-10-17T01:15:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-breakthrough-therapy-designation-to-bpl-003-nasal-spray-for-treatment-resistant-depression 2025-10-17T01:15:35+00:00 hourly 0.9 https://trial.medpath.com/news/kezar-life-sciences-faces-fda-setback-for-autoimmune-hepatitis-drug-explores-strategic-alternatives 2025-10-16T23:06:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kezar-life-sciences-faces-fda-setback-for-autoimmune-hepatitis-drug-explores-strategic-alternatives 2025-10-16T23:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/aligos-therapeutics-receives-usan-approval-for-pevifoscorvir-sodium-first-generic-name-for-hepatitis-b-drug-candidate 2025-10-16T21:23:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aligos-therapeutics-receives-usan-approval-for-pevifoscorvir-sodium-first-generic-name-for-hepatitis-b-drug-candidate 2025-10-16T21:23:06+00:00 hourly 0.9 https://trial.medpath.com/news/california-launches-first-state-branded-insulin-program-offering-55-five-pack-to-combat-high-drug-costs 2025-10-16T21:22:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/california-launches-first-state-branded-insulin-program-offering-55-five-pack-to-combat-high-drug-costs 2025-10-16T21:22:12+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-safety-alert-on-radiofrequency-microneedling-devices-following-reports-of-severe-complications 2025-10-16T21:20:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-safety-alert-on-radiofrequency-microneedling-devices-following-reports-of-severe-complications 2025-10-16T21:20:48+00:00 hourly 0.9 https://trial.medpath.com/news/allergy-therapeutics-reports-positive-progress-in-phase-2a-trial-of-vlp-peanut-allergy-vaccine 2025-10-16T21:19:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/allergy-therapeutics-reports-positive-progress-in-phase-2a-trial-of-vlp-peanut-allergy-vaccine 2025-10-16T21:19:25+00:00 hourly 0.9 https://trial.medpath.com/news/cellectis-reports-promising-phase-1-results-for-lasme-cel-in-relapsed-refractory-b-all-advances-to-pivotal-phase-2 2025-10-16T21:18:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cellectis-reports-promising-phase-1-results-for-lasme-cel-in-relapsed-refractory-b-all-advances-to-pivotal-phase-2 2025-10-16T21:18:42+00:00 hourly 0.9 https://trial.medpath.com/news/thymic-health-emerges-as-novel-biomarker-for-predicting-immunotherapy-response-across-cancer-types 2025-10-16T21:18:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/thymic-health-emerges-as-novel-biomarker-for-predicting-immunotherapy-response-across-cancer-types 2025-10-16T21:18:24+00:00 hourly 0.9 https://trial.medpath.com/news/xbrane-biopharma-secures-sek-60-million-conditional-financing-ahead-of-lucamzi-fda-decision 2025-10-16T21:18:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/xbrane-biopharma-secures-sek-60-million-conditional-financing-ahead-of-lucamzi-fda-decision 2025-10-16T21:18:13+00:00 hourly 0.9 https://trial.medpath.com/news/extended-release-oral-minoxidil-shows-promise-as-first-fda-approved-hair-loss-treatment-for-women 2025-10-16T21:16:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/extended-release-oral-minoxidil-shows-promise-as-first-fda-approved-hair-loss-treatment-for-women 2025-10-16T21:16:56+00:00 hourly 0.9 https://trial.medpath.com/news/uspto-proposes-major-restrictions-on-inter-partes-review-patent-challenges 2025-10-16T21:16:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uspto-proposes-major-restrictions-on-inter-partes-review-patent-challenges 2025-10-16T21:16:37+00:00 hourly 0.9 https://trial.medpath.com/news/veeva-systems-and-openevidence-partner-to-launch-ai-powered-clinical-trial-access-platform 2025-10-16T17:25:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/veeva-systems-and-openevidence-partner-to-launch-ai-powered-clinical-trial-access-platform 2025-10-16T17:25:55+00:00 hourly 0.9 https://trial.medpath.com/news/gene-therapy-achieves-95-success-rate-in-treating-ada-scid-bubble-boy-disease 2025-10-16T17:25:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gene-therapy-achieves-95-success-rate-in-treating-ada-scid-bubble-boy-disease 2025-10-16T17:25:47+00:00 hourly 0.9 https://trial.medpath.com/news/akari-therapeutics-secures-5-million-financing-to-advance-novel-adc-platform-with-spliceosome-modulator-payload 2025-10-16T17:25:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/akari-therapeutics-secures-5-million-financing-to-advance-novel-adc-platform-with-spliceosome-modulator-payload 2025-10-16T17:25:37+00:00 hourly 0.9 https://trial.medpath.com/news/bridgene-biosciences-secures-28-million-series-b-funding-to-advance-tead-inhibitor-bgc-515-toward-phase-2 2025-10-16T17:22:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bridgene-biosciences-secures-28-million-series-b-funding-to-advance-tead-inhibitor-bgc-515-toward-phase-2 2025-10-16T17:22:10+00:00 hourly 0.9 https://trial.medpath.com/news/genentech-launches-direct-to-patient-program-for-xofluza-offering-70-price-reduction 2025-10-16T17:21:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genentech-launches-direct-to-patient-program-for-xofluza-offering-70-price-reduction 2025-10-16T17:21:49+00:00 hourly 0.9 https://trial.medpath.com/news/me-therapeutics-secures-exclusive-license-for-cd22-nanobody-technology-to-advance-next-generation-car-cell-therapies 2025-10-16T17:21:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/me-therapeutics-secures-exclusive-license-for-cd22-nanobody-technology-to-advance-next-generation-car-cell-therapies 2025-10-16T17:21:44+00:00 hourly 0.9 https://trial.medpath.com/news/taiho-pharmaceutical-exercises-option-for-casdatifan-hif-2a-inhibitor-in-asia-pacific-territories 2025-10-16T17:20:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/taiho-pharmaceutical-exercises-option-for-casdatifan-hif-2a-inhibitor-in-asia-pacific-territories 2025-10-16T17:20:35+00:00 hourly 0.9 https://trial.medpath.com/news/first-parkinson-s-patient-shows-significant-motor-improvement-with-ux-da001-autologous-cell-therapy 2025-10-16T17:20:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-parkinson-s-patient-shows-significant-motor-improvement-with-ux-da001-autologous-cell-therapy 2025-10-16T17:20:21+00:00 hourly 0.9 https://trial.medpath.com/news/researchers-plan-fda-application-for-groundbreaking-crispr-base-editing-trial-following-baby-kj-s-successful-treatment 2025-10-16T17:20:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/researchers-plan-fda-application-for-groundbreaking-crispr-base-editing-trial-following-baby-kj-s-successful-treatment 2025-10-16T17:20:12+00:00 hourly 0.9 https://trial.medpath.com/news/advancell-appoints-alpha-therapy-pioneer-andrew-kay-as-board-chair-to-lead-psma-targeted-radiopharmaceutical-development 2025-10-16T17:19:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/advancell-appoints-alpha-therapy-pioneer-andrew-kay-as-board-chair-to-lead-psma-targeted-radiopharmaceutical-development 2025-10-16T17:19:24+00:00 hourly 0.9 https://trial.medpath.com/news/esperion-advances-esp-2001-for-primary-sclerosing-cholangitis-targeting-1-billion-market-opportunity 2025-10-16T17:18:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/esperion-advances-esp-2001-for-primary-sclerosing-cholangitis-targeting-1-billion-market-opportunity 2025-10-16T17:18:51+00:00 hourly 0.9 https://trial.medpath.com/news/us-orphan-drug-market-poised-to-exceed-190-billion-by-2030-as-fda-designations-accelerate-rare-disease-therapy-development 2025-10-16T17:18:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/us-orphan-drug-market-poised-to-exceed-190-billion-by-2030-as-fda-designations-accelerate-rare-disease-therapy-development 2025-10-16T17:18:40+00:00 hourly 0.9 https://trial.medpath.com/news/calico-appoints-former-abbvie-executive-philip-kym-as-head-of-drug-discovery-to-advance-anti-aging-therapeutics 2025-10-16T17:18:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/calico-appoints-former-abbvie-executive-philip-kym-as-head-of-drug-discovery-to-advance-anti-aging-therapeutics 2025-10-16T17:18:26+00:00 hourly 0.9 https://trial.medpath.com/news/doron-therapeutics-initiates-phase-3-trial-of-motys-biologic-therapy-for-knee-osteoarthritis 2025-10-16T17:17:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/doron-therapeutics-initiates-phase-3-trial-of-motys-biologic-therapy-for-knee-osteoarthritis 2025-10-16T17:17:43+00:00 hourly 0.9 https://trial.medpath.com/news/imbria-pharmaceuticals-partners-with-patient-advocacy-group-to-accelerate-recruitment-for-novel-heart-disease-trial 2025-10-16T17:15:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/imbria-pharmaceuticals-partners-with-patient-advocacy-group-to-accelerate-recruitment-for-novel-heart-disease-trial 2025-10-16T17:15:56+00:00 hourly 0.9 https://trial.medpath.com/news/sunshine-biopharma-launches-generic-pravastatin-in-canada-through-nora-pharma-subsidiary 2025-10-16T17:15:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sunshine-biopharma-launches-generic-pravastatin-in-canada-through-nora-pharma-subsidiary 2025-10-16T17:15:03+00:00 hourly 0.9 https://trial.medpath.com/news/senescent-immune-cells-drive-immunotherapy-resistance-in-cancer-through-sasp-mediated-tumor-microenvironment-remodeling 2025-10-16T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/senescent-immune-cells-drive-immunotherapy-resistance-in-cancer-through-sasp-mediated-tumor-microenvironment-remodeling 2025-10-16T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/foghorn-therapeutics-reports-breakthrough-progress-in-selective-arid1b-degrader-for-cancer-treatment 2025-10-16T13:24:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/foghorn-therapeutics-reports-breakthrough-progress-in-selective-arid1b-degrader-for-cancer-treatment 2025-10-16T13:24:02+00:00 hourly 0.9 https://trial.medpath.com/news/halda-therapeutics-hld-0915-shows-promising-first-in-human-results-in-advanced-prostate-cancer 2025-10-16T13:23:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/halda-therapeutics-hld-0915-shows-promising-first-in-human-results-in-advanced-prostate-cancer 2025-10-16T13:23:06+00:00 hourly 0.9 https://trial.medpath.com/news/google-deepmind-s-ai-model-discovers-novel-cancer-immunotherapy-approach-through-cell-level-analysis 2025-10-16T13:20:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/google-deepmind-s-ai-model-discovers-novel-cancer-immunotherapy-approach-through-cell-level-analysis 2025-10-16T13:20:55+00:00 hourly 0.9 https://trial.medpath.com/news/sglt-2-inhibitors-show-11-reduction-in-autoimmune-disease-risk-in-large-korean-study 2025-10-16T13:20:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sglt-2-inhibitors-show-11-reduction-in-autoimmune-disease-risk-in-large-korean-study 2025-10-16T13:20:46+00:00 hourly 0.9 https://trial.medpath.com/news/veradermics-secures-150-million-series-c-to-advance-first-extended-release-oral-minoxidil-through-phase-3-trials 2025-10-16T13:18:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/veradermics-secures-150-million-series-c-to-advance-first-extended-release-oral-minoxidil-through-phase-3-trials 2025-10-16T13:18:55+00:00 hourly 0.9 https://trial.medpath.com/news/dianthus-therapeutics-secures-exclusive-license-for-dnth212-a-dual-target-autoimmune-therapy 2025-10-16T13:17:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dianthus-therapeutics-secures-exclusive-license-for-dnth212-a-dual-target-autoimmune-therapy 2025-10-16T13:17:59+00:00 hourly 0.9 https://trial.medpath.com/news/graph-ai-secures-3m-seed-funding-to-transform-drug-safety-monitoring-with-ai-native-platform 2025-10-16T13:17:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/graph-ai-secures-3m-seed-funding-to-transform-drug-safety-monitoring-with-ai-native-platform 2025-10-16T13:17:25+00:00 hourly 0.9 https://trial.medpath.com/news/astellas-vyloy-fails-phase-2-pancreatic-cancer-trial-despite-gastric-cancer-success 2025-10-16T13:17:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astellas-vyloy-fails-phase-2-pancreatic-cancer-trial-despite-gastric-cancer-success 2025-10-16T13:17:19+00:00 hourly 0.9 https://trial.medpath.com/news/peptilogics-raises-78-million-to-advance-zaloganan-into-pivotal-phase-2-3-trial-for-prosthetic-joint-infections 2025-10-16T13:16:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/peptilogics-raises-78-million-to-advance-zaloganan-into-pivotal-phase-2-3-trial-for-prosthetic-joint-infections 2025-10-16T13:16:57+00:00 hourly 0.9 https://trial.medpath.com/news/praxis-precision-medicines-reports-positive-phase-3-results-for-ulixacaltamide-in-essential-tremor 2025-10-16T13:16:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/praxis-precision-medicines-reports-positive-phase-3-results-for-ulixacaltamide-in-essential-tremor 2025-10-16T13:16:21+00:00 hourly 0.9 https://trial.medpath.com/news/adcytherix-secures-eur105m-series-a-to-advance-novel-adc-pipeline-into-clinical-trials 2025-10-16T13:16:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adcytherix-secures-eur105m-series-a-to-advance-novel-adc-pipeline-into-clinical-trials 2025-10-16T13:16:15+00:00 hourly 0.9 https://trial.medpath.com/news/california-accelerates-psychedelic-research-for-ptsd-treatment-following-veteran-backed-legislation 2025-10-16T13:16:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/california-accelerates-psychedelic-research-for-ptsd-treatment-following-veteran-backed-legislation 2025-10-16T13:16:08+00:00 hourly 0.9 https://trial.medpath.com/news/world-s-largest-parkinson-s-clinical-trial-platform-launches-in-uk-testing-multiple-disease-modifying-therapies-simultaneously 2025-10-16T13:15:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/world-s-largest-parkinson-s-clinical-trial-platform-launches-in-uk-testing-multiple-disease-modifying-therapies-simultaneously 2025-10-16T13:15:57+00:00 hourly 0.9 https://trial.medpath.com/news/critical-path-institute-launches-disease-modeling-coalition-to-accelerate-pediatric-ibd-drug-development 2025-10-16T13:15:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/critical-path-institute-launches-disease-modeling-coalition-to-accelerate-pediatric-ibd-drug-development 2025-10-16T13:15:31+00:00 hourly 0.9 https://trial.medpath.com/news/biocon-biologics-and-civica-expand-partnership-to-launch-private-label-insulin-glargine-in-us-market 2025-10-16T13:15:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biocon-biologics-and-civica-expand-partnership-to-launch-private-label-insulin-glargine-in-us-market 2025-10-16T13:15:28+00:00 hourly 0.9 https://trial.medpath.com/news/intensity-therapeutics-raises-4-million-to-advance-intratumoral-cancer-therapy-clinical-trials 2025-10-16T12:26:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/intensity-therapeutics-raises-4-million-to-advance-intratumoral-cancer-therapy-clinical-trials 2025-10-16T12:26:00+00:00 hourly 0.9 https://trial.medpath.com/news/clearb-therapeutics-advances-clb-4000-therapeutic-vaccine-for-chronic-hepatitis-b-after-positive-sentinel-safety-review 2025-10-16T09:18:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clearb-therapeutics-advances-clb-4000-therapeutic-vaccine-for-chronic-hepatitis-b-after-positive-sentinel-safety-review 2025-10-16T09:18:51+00:00 hourly 0.9 https://trial.medpath.com/news/enterome-s-eo2463-receives-fda-fast-track-designation-for-follicular-lymphoma-watch-and-wait-treatment 2025-10-16T09:17:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/enterome-s-eo2463-receives-fda-fast-track-designation-for-follicular-lymphoma-watch-and-wait-treatment 2025-10-16T09:17:27+00:00 hourly 0.9 https://trial.medpath.com/news/solvonis-secures-ps1-25-million-funding-to-advance-cns-drug-development-pipeline 2025-10-16T09:16:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/solvonis-secures-ps1-25-million-funding-to-advance-cns-drug-development-pipeline 2025-10-16T09:16:40+00:00 hourly 0.9 https://trial.medpath.com/news/18-million-dod-funded-trial-to-test-metformin-for-idiopathic-pulmonary-fibrosis-in-veterans 2025-10-16T09:15:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/18-million-dod-funded-trial-to-test-metformin-for-idiopathic-pulmonary-fibrosis-in-veterans 2025-10-16T09:15:40+00:00 hourly 0.9 https://trial.medpath.com/news/pelage-pharmaceuticals-secures-120m-series-b-to-advance-hair-loss-stem-cell-therapy-toward-phase-iii 2025-10-16T05:28:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pelage-pharmaceuticals-secures-120m-series-b-to-advance-hair-loss-stem-cell-therapy-toward-phase-iii 2025-10-16T05:28:46+00:00 hourly 0.9 https://trial.medpath.com/news/step-pharma-secures-eur38-million-series-c-to-advance-ctps1-inhibitor-dencatistat-across-multiple-cancer-indications 2025-10-16T01:20:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/step-pharma-secures-eur38-million-series-c-to-advance-ctps1-inhibitor-dencatistat-across-multiple-cancer-indications 2025-10-16T01:20:13+00:00 hourly 0.9 https://trial.medpath.com/news/innocan-pharma-secures-patent-for-lpt-cbd-technology-in-japan-s-102-billion-pharmaceutical-market 2025-10-16T01:19:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/innocan-pharma-secures-patent-for-lpt-cbd-technology-in-japan-s-102-billion-pharmaceutical-market 2025-10-16T01:19:12+00:00 hourly 0.9 https://trial.medpath.com/news/viatris-acquires-aculys-pharma-gains-rights-to-cns-therapies-pitolisant-and-spydia-in-japan 2025-10-16T01:18:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/viatris-acquires-aculys-pharma-gains-rights-to-cns-therapies-pitolisant-and-spydia-in-japan 2025-10-16T01:18:40+00:00 hourly 0.9 https://trial.medpath.com/news/gene-therapy-achieves-95-success-rate-in-treating-children-with-rare-immune-disorder-ada-scid 2025-10-16T01:17:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gene-therapy-achieves-95-success-rate-in-treating-children-with-rare-immune-disorder-ada-scid 2025-10-16T01:17:30+00:00 hourly 0.9 https://trial.medpath.com/news/brain-metastasis-from-breast-cancer-pipeline-shows-promise-with-10-therapies-in-development 2025-10-16T01:16:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brain-metastasis-from-breast-cancer-pipeline-shows-promise-with-10-therapies-in-development 2025-10-16T01:16:49+00:00 hourly 0.9 https://trial.medpath.com/news/smartlens-raises-5-2-million-to-advance-fda-clearance-of-electronics-free-contact-lens-for-continuous-glaucoma-monitoring 2025-10-16T01:15:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/smartlens-raises-5-2-million-to-advance-fda-clearance-of-electronics-free-contact-lens-for-continuous-glaucoma-monitoring 2025-10-16T01:15:39+00:00 hourly 0.9 https://trial.medpath.com/news/rapid-sublocade-induction-shows-superior-patient-retention-in-opioid-use-disorder-treatment 2025-10-16T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rapid-sublocade-induction-shows-superior-patient-retention-in-opioid-use-disorder-treatment 2025-10-16T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/liberate-bio-achieves-first-in-vivo-car-m-b-cell-depletion-in-non-human-primates 2025-10-15T21:26:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/liberate-bio-achieves-first-in-vivo-car-m-b-cell-depletion-in-non-human-primates 2025-10-15T21:26:21+00:00 hourly 0.9 https://trial.medpath.com/news/rna-sequencing-guided-treatment-selection-shows-promise-in-metastatic-renal-cell-carcinoma 2025-10-15T21:26:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rna-sequencing-guided-treatment-selection-shows-promise-in-metastatic-renal-cell-carcinoma 2025-10-15T21:26:05+00:00 hourly 0.9 https://trial.medpath.com/news/scisparc-transfers-11-6m-cns-drug-portfolio-to-canadian-public-company-in-strategic-restructuring 2025-10-15T21:21:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scisparc-transfers-11-6m-cns-drug-portfolio-to-canadian-public-company-in-strategic-restructuring 2025-10-15T21:21:22+00:00 hourly 0.9 https://trial.medpath.com/news/cd19-car-t-cell-therapy-demonstrates-promising-activity-in-richter-transformation-despite-modest-outcomes 2025-10-15T21:20:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cd19-car-t-cell-therapy-demonstrates-promising-activity-in-richter-transformation-despite-modest-outcomes 2025-10-15T21:20:41+00:00 hourly 0.9 https://trial.medpath.com/news/dual-cd19-cd22-car-t-therapy-achieves-durable-remission-in-refractory-plasmablastic-lymphoma-case 2025-10-15T21:20:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dual-cd19-cd22-car-t-therapy-achieves-durable-remission-in-refractory-plasmablastic-lymphoma-case 2025-10-15T21:20:01+00:00 hourly 0.9 https://trial.medpath.com/news/absci-accelerates-abs-201-hair-loss-treatment-trial-announces-expert-seminar-for-december 2025-10-15T21:19:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/absci-accelerates-abs-201-hair-loss-treatment-trial-announces-expert-seminar-for-december 2025-10-15T21:19:31+00:00 hourly 0.9 https://trial.medpath.com/news/first-gene-therapy-targeting-brain-white-matter-shows-breakthrough-results-in-fatal-childhood-disease 2025-10-15T21:18:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-gene-therapy-targeting-brain-white-matter-shows-breakthrough-results-in-fatal-childhood-disease 2025-10-15T21:18:47+00:00 hourly 0.9 https://trial.medpath.com/news/crispr-therapy-reduces-influenza-a-viral-load-by-50-in-human-lung-chip-model 2025-10-15T21:18:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/crispr-therapy-reduces-influenza-a-viral-load-by-50-in-human-lung-chip-model 2025-10-15T21:18:36+00:00 hourly 0.9 https://trial.medpath.com/news/pelage-pharmaceuticals-raises-120-million-for-novel-hair-loss-therapy-targeting-stem-cell-regeneration 2025-10-15T21:18:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pelage-pharmaceuticals-raises-120-million-for-novel-hair-loss-therapy-targeting-stem-cell-regeneration 2025-10-15T21:18:25+00:00 hourly 0.9 https://trial.medpath.com/news/essilorluxottica-acquires-ai-powered-retinai-to-advance-eye-disease-diagnosis-and-drug-development 2025-10-15T21:17:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/essilorluxottica-acquires-ai-powered-retinai-to-advance-eye-disease-diagnosis-and-drug-development 2025-10-15T21:17:19+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-fast-track-status-to-enterome-s-eo2463-for-follicular-lymphoma-treatment 2025-10-15T21:17:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-fast-track-status-to-enterome-s-eo2463-for-follicular-lymphoma-treatment 2025-10-15T21:17:17+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-1-minute-hiv-self-test-revolutionizing-at-home-diagnostics 2025-10-15T21:15:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-first-1-minute-hiv-self-test-revolutionizing-at-home-diagnostics 2025-10-15T21:15:54+00:00 hourly 0.9 https://trial.medpath.com/news/peptidream-pdradiopharma-and-curium-initiate-registrational-trial-for-64cu-psma-i-t-in-japanese-prostate-cancer-patients 2025-10-15T17:29:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/peptidream-pdradiopharma-and-curium-initiate-registrational-trial-for-64cu-psma-i-t-in-japanese-prostate-cancer-patients 2025-10-15T17:29:31+00:00 hourly 0.9 https://trial.medpath.com/news/cleveland-clinic-partners-with-khosla-ventures-to-accelerate-healthcare-innovation-through-strategic-collaboration 2025-10-15T17:23:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cleveland-clinic-partners-with-khosla-ventures-to-accelerate-healthcare-innovation-through-strategic-collaboration 2025-10-15T17:23:43+00:00 hourly 0.9 https://trial.medpath.com/news/mmi-launches-largest-u-s-clinical-trial-for-robotic-microsurgery-with-first-patient-enrollment 2025-10-15T17:23:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mmi-launches-largest-u-s-clinical-trial-for-robotic-microsurgery-with-first-patient-enrollment 2025-10-15T17:23:14+00:00 hourly 0.9 https://trial.medpath.com/news/sk-bioscience-initiates-first-in-human-trial-for-universal-coronavirus-vaccine-gbp511 2025-10-15T17:22:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sk-bioscience-initiates-first-in-human-trial-for-universal-coronavirus-vaccine-gbp511 2025-10-15T17:22:49+00:00 hourly 0.9 https://trial.medpath.com/news/fda-accepts-chiesi-s-new-drug-application-for-triple-combination-asthma-inhaler 2025-10-15T17:21:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-accepts-chiesi-s-new-drug-application-for-triple-combination-asthma-inhaler 2025-10-15T17:21:26+00:00 hourly 0.9 https://trial.medpath.com/news/biomarker-analysis-identifies-predictors-of-long-term-survival-in-glioblastoma-patients-receiving-survaxm-immunotherapy 2025-10-15T17:21:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biomarker-analysis-identifies-predictors-of-long-term-survival-in-glioblastoma-patients-receiving-survaxm-immunotherapy 2025-10-15T17:21:21+00:00 hourly 0.9 https://trial.medpath.com/news/jacobio-pharma-secures-rmb-200-million-strategic-partnership-with-oceanpine-capital-to-advance-kras-oncology-pipeline 2025-10-15T17:21:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jacobio-pharma-secures-rmb-200-million-strategic-partnership-with-oceanpine-capital-to-advance-kras-oncology-pipeline 2025-10-15T17:21:12+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-acquires-zaltenibart-from-omeros-for-up-to-2-1-billion-to-target-rare-blood-and-kidney-disorders 2025-10-15T17:20:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novo-nordisk-acquires-zaltenibart-from-omeros-for-up-to-2-1-billion-to-target-rare-blood-and-kidney-disorders 2025-10-15T17:20:58+00:00 hourly 0.9 https://trial.medpath.com/news/merck-acquires-jsr-life-sciences-chromatography-business-to-strengthen-protein-a-purification-capabilities 2025-10-15T17:20:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-acquires-jsr-life-sciences-chromatography-business-to-strengthen-protein-a-purification-capabilities 2025-10-15T17:20:53+00:00 hourly 0.9 https://trial.medpath.com/news/enveric-biosciences-engages-ip-firm-to-defend-patent-claims-related-to-abbvie-s-1-2-billion-bretisilocin-acquisition 2025-10-15T17:20:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/enveric-biosciences-engages-ip-firm-to-defend-patent-claims-related-to-abbvie-s-1-2-billion-bretisilocin-acquisition 2025-10-15T17:20:40+00:00 hourly 0.9 https://trial.medpath.com/news/syngene-international-expands-peptide-manufacturing-and-automation-capabilities-to-accelerate-drug-development 2025-10-15T17:19:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/syngene-international-expands-peptide-manufacturing-and-automation-capabilities-to-accelerate-drug-development 2025-10-15T17:19:22+00:00 hourly 0.9 https://trial.medpath.com/news/eikon-therapeutics-to-present-phase-2-data-on-novel-tlr7-8-co-agonist-eik1001-for-advanced-nsclc-at-esmo-2025 2025-10-15T17:19:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eikon-therapeutics-to-present-phase-2-data-on-novel-tlr7-8-co-agonist-eik1001-for-advanced-nsclc-at-esmo-2025 2025-10-15T17:19:14+00:00 hourly 0.9 https://trial.medpath.com/news/rocket-doctor-ai-secures-2m-nih-grant-to-develop-ai-powered-family-medical-history-tool-for-health-equity 2025-10-15T17:19:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rocket-doctor-ai-secures-2m-nih-grant-to-develop-ai-powered-family-medical-history-tool-for-health-equity 2025-10-15T17:19:09+00:00 hourly 0.9 https://trial.medpath.com/news/oncodesign-precision-medicine-secures-eur250000-regional-grant-to-advance-cancer-drug-development 2025-10-15T17:18:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oncodesign-precision-medicine-secures-eur250000-regional-grant-to-advance-cancer-drug-development 2025-10-15T17:18:04+00:00 hourly 0.9 https://trial.medpath.com/news/oncohost-s-prophet-model-shows-promise-for-optimizing-melanoma-treatment-selection-at-esmo-2025 2025-10-15T17:17:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oncohost-s-prophet-model-shows-promise-for-optimizing-melanoma-treatment-selection-at-esmo-2025 2025-10-15T17:17:57+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-fast-track-designation-to-ng-350a-for-mismatch-repair-proficient-locally-advanced-rectal-cancer 2025-10-15T17:17:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-fast-track-designation-to-ng-350a-for-mismatch-repair-proficient-locally-advanced-rectal-cancer 2025-10-15T17:17:52+00:00 hourly 0.9 https://trial.medpath.com/news/anteris-technologies-receives-european-regulatory-clearance-for-duravr-global-pivotal-trial-in-aortic-stenosis 2025-10-15T17:15:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/anteris-technologies-receives-european-regulatory-clearance-for-duravr-global-pivotal-trial-in-aortic-stenosis 2025-10-15T17:15:36+00:00 hourly 0.9 https://trial.medpath.com/news/nice-rejects-vorasidenib-for-nhs-use-despite-positive-brain-cancer-trial-results 2025-10-15T17:15:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nice-rejects-vorasidenib-for-nhs-use-despite-positive-brain-cancer-trial-results 2025-10-15T17:15:28+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-pivotal-trial-for-novel-tricuspid-valve-repair-device-mia-t 2025-10-15T13:25:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-pivotal-trial-for-novel-tricuspid-valve-repair-device-mia-t 2025-10-15T13:25:58+00:00 hourly 0.9 https://trial.medpath.com/news/landmark-bio-partners-with-mass-general-brigham-to-accelerate-cell-and-gene-therapy-development 2025-10-15T13:25:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/landmark-bio-partners-with-mass-general-brigham-to-accelerate-cell-and-gene-therapy-development 2025-10-15T13:25:46+00:00 hourly 0.9 https://trial.medpath.com/news/mission-therapeutics-secures-13-3m-to-advance-first-in-class-parkinson-s-disease-drug-mtx325-into-phase-ib-trials 2025-10-15T13:25:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mission-therapeutics-secures-13-3m-to-advance-first-in-class-parkinson-s-disease-drug-mtx325-into-phase-ib-trials 2025-10-15T13:25:19+00:00 hourly 0.9 https://trial.medpath.com/news/regeneron-presents-new-libtayo-data-at-esmo-2025-showcasing-patient-centric-every-6-week-dosing-for-high-risk-skin-cancer 2025-10-15T13:23:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regeneron-presents-new-libtayo-data-at-esmo-2025-showcasing-patient-centric-every-6-week-dosing-for-high-risk-skin-cancer 2025-10-15T13:23:26+00:00 hourly 0.9 https://trial.medpath.com/news/mrna-delivered-nanobodies-show-promise-against-colorectal-cancer-in-preclinical-study 2025-10-15T13:22:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mrna-delivered-nanobodies-show-promise-against-colorectal-cancer-in-preclinical-study 2025-10-15T13:22:14+00:00 hourly 0.9 https://trial.medpath.com/news/neoadjuvant-radiotherapy-shows-survival-benefit-in-locally-advanced-rectal-cancer-despite-increased-stoma-risk 2025-10-15T13:21:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neoadjuvant-radiotherapy-shows-survival-benefit-in-locally-advanced-rectal-cancer-despite-increased-stoma-risk 2025-10-15T13:21:22+00:00 hourly 0.9 https://trial.medpath.com/news/anti-pd-1-immunotherapy-shows-promise-for-drug-free-hiv-control-in-phase-1-trial 2025-10-15T13:21:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/anti-pd-1-immunotherapy-shows-promise-for-drug-free-hiv-control-in-phase-1-trial 2025-10-15T13:21:16+00:00 hourly 0.9 https://trial.medpath.com/news/hanmi-pharmaceutical-s-dual-ezh1-2-inhibitor-shows-promising-antitumor-activity-in-phase-1-trial 2025-10-15T13:20:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hanmi-pharmaceutical-s-dual-ezh1-2-inhibitor-shows-promising-antitumor-activity-in-phase-1-trial 2025-10-15T13:20:26+00:00 hourly 0.9 https://trial.medpath.com/news/transpire-bio-receives-fda-orphan-drug-designation-for-inhaled-therapies-targeting-ipf-and-glioblastoma 2025-10-15T13:20:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/transpire-bio-receives-fda-orphan-drug-designation-for-inhaled-therapies-targeting-ipf-and-glioblastoma 2025-10-15T13:20:16+00:00 hourly 0.9 https://trial.medpath.com/news/bexorg-secures-42-5m-to-revolutionize-cns-drug-discovery-with-ai-powered-whole-human-brain-platform 2025-10-15T13:20:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bexorg-secures-42-5m-to-revolutionize-cns-drug-discovery-with-ai-powered-whole-human-brain-platform 2025-10-15T13:20:10+00:00 hourly 0.9 https://trial.medpath.com/news/indivi-and-clouds-of-care-partner-to-advance-deep-phenotyping-technologies-for-alzheimer-s-and-parkinson-s-drug-development 2025-10-15T13:20:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/indivi-and-clouds-of-care-partner-to-advance-deep-phenotyping-technologies-for-alzheimer-s-and-parkinson-s-drug-development 2025-10-15T13:20:07+00:00 hourly 0.9 https://trial.medpath.com/news/omnix-medical-raises-25-million-series-c-to-advance-novel-antimicrobial-against-drug-resistant-infections 2025-10-15T13:19:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/omnix-medical-raises-25-million-series-c-to-advance-novel-antimicrobial-against-drug-resistant-infections 2025-10-15T13:19:58+00:00 hourly 0.9 https://trial.medpath.com/news/caps-medical-s-plasmasure-system-receives-fda-breakthrough-device-designation-for-non-muscle-invasive-bladder-cancer-treatment 2025-10-15T13:19:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/caps-medical-s-plasmasure-system-receives-fda-breakthrough-device-designation-for-non-muscle-invasive-bladder-cancer-treatment 2025-10-15T13:19:33+00:00 hourly 0.9 https://trial.medpath.com/news/lisaftoclax-shows-promise-in-relapsed-multiple-myeloma-and-al-amyloidosis-across-cytogenetic-profiles 2025-10-15T13:19:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lisaftoclax-shows-promise-in-relapsed-multiple-myeloma-and-al-amyloidosis-across-cytogenetic-profiles 2025-10-15T13:19:04+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-s-tukysa-achieves-phase-iii-success-in-her2-positive-breast-cancer-maintenance-therapy 2025-10-15T13:18:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pfizer-s-tukysa-achieves-phase-iii-success-in-her2-positive-breast-cancer-maintenance-therapy 2025-10-15T13:18:17+00:00 hourly 0.9 https://trial.medpath.com/news/mabwell-s-b7-h3-targeting-adc-7mw3711-shows-promising-efficacy-in-advanced-solid-tumors 2025-10-15T09:22:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mabwell-s-b7-h3-targeting-adc-7mw3711-shows-promising-efficacy-in-advanced-solid-tumors 2025-10-15T09:22:09+00:00 hourly 0.9 https://trial.medpath.com/news/spyglass-pharma-s-bim-iol-system-shows-42-iop-reduction-at-24-months-in-glaucoma-patients 2025-10-15T09:21:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/spyglass-pharma-s-bim-iol-system-shows-42-iop-reduction-at-24-months-in-glaucoma-patients 2025-10-15T09:21:33+00:00 hourly 0.9 https://trial.medpath.com/news/combined-mrna-therapy-shows-promise-for-preventing-respiratory-distress-in-preterm-infants 2025-10-15T09:20:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/combined-mrna-therapy-shows-promise-for-preventing-respiratory-distress-in-preterm-infants 2025-10-15T09:20:21+00:00 hourly 0.9 https://trial.medpath.com/news/celltrion-secures-first-mover-advantage-in-new-zealand-with-stelara-biosimilar-steqeyma-approval 2025-10-15T09:18:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/celltrion-secures-first-mover-advantage-in-new-zealand-with-stelara-biosimilar-steqeyma-approval 2025-10-15T09:18:37+00:00 hourly 0.9 https://trial.medpath.com/news/dnmt-inhibitors-combined-with-anti-pd-1-therapy-show-promise-for-refractory-nk-t-cell-lymphoma 2025-10-15T09:17:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dnmt-inhibitors-combined-with-anti-pd-1-therapy-show-promise-for-refractory-nk-t-cell-lymphoma 2025-10-15T09:17:03+00:00 hourly 0.9 https://trial.medpath.com/news/propanc-biopharma-secures-100-million-financing-to-advance-cancer-stem-cell-therapy-prp-toward-first-in-human-trial 2025-10-15T08:44:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/propanc-biopharma-secures-100-million-financing-to-advance-cancer-stem-cell-therapy-prp-toward-first-in-human-trial 2025-10-15T08:44:00+00:00 hourly 0.9 https://trial.medpath.com/news/nona-biosciences-appoints-dr-di-hong-as-ceo-to-advance-antibody-discovery-platform 2025-10-15T05:19:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nona-biosciences-appoints-dr-di-hong-as-ceo-to-advance-antibody-discovery-platform 2025-10-15T05:19:30+00:00 hourly 0.9 https://trial.medpath.com/news/orum-therapeutics-strengthens-degrader-antibody-conjugate-platform-with-key-executive-appointment 2025-10-15T05:19:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/orum-therapeutics-strengthens-degrader-antibody-conjugate-platform-with-key-executive-appointment 2025-10-15T05:19:27+00:00 hourly 0.9 https://trial.medpath.com/news/skin-elements-raises-2-5-million-to-commercialize-se-formula-biotechnology-platform 2025-10-15T05:18:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/skin-elements-raises-2-5-million-to-commercialize-se-formula-biotechnology-platform 2025-10-15T05:18:50+00:00 hourly 0.9 https://trial.medpath.com/news/nucana-reports-durable-responses-with-nuc-3373-plus-pembrolizumab-in-heavily-pre-treated-cancer-patients 2025-10-15T01:21:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nucana-reports-durable-responses-with-nuc-3373-plus-pembrolizumab-in-heavily-pre-treated-cancer-patients 2025-10-15T01:21:18+00:00 hourly 0.9 https://trial.medpath.com/news/hyperpolarized-nmr-reveals-real-time-metabolic-dynamics-in-car-t-cell-manufacturing 2025-10-15T01:19:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hyperpolarized-nmr-reveals-real-time-metabolic-dynamics-in-car-t-cell-manufacturing 2025-10-15T01:19:08+00:00 hourly 0.9 https://trial.medpath.com/news/privo-technologies-completes-phase-2-run-in-for-prv111-oral-cancer-patch-shows-promise-for-surgery-sparing-treatment 2025-10-15T01:19:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/privo-technologies-completes-phase-2-run-in-for-prv111-oral-cancer-patch-shows-promise-for-surgery-sparing-treatment 2025-10-15T01:19:00+00:00 hourly 0.9 https://trial.medpath.com/news/uk-s-innovative-licensing-and-access-pathway-awards-first-innovation-passports-to-three-rare-disease-therapies 2025-10-15T01:18:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-s-innovative-licensing-and-access-pathway-awards-first-innovation-passports-to-three-rare-disease-therapies 2025-10-15T01:18:46+00:00 hourly 0.9 https://trial.medpath.com/news/ou-health-stephenson-cancer-center-doubles-phase-1-clinical-trial-capacity-with-35-million-federal-investment 2025-10-15T01:16:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ou-health-stephenson-cancer-center-doubles-phase-1-clinical-trial-capacity-with-35-million-federal-investment 2025-10-15T01:16:01+00:00 hourly 0.9 https://trial.medpath.com/news/alleviate-health-raises-4-3m-to-transform-clinical-trial-patient-recruitment-with-ai-technology 2025-10-15T01:15:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alleviate-health-raises-4-3m-to-transform-clinical-trial-patient-recruitment-with-ai-technology 2025-10-15T01:15:56+00:00 hourly 0.9 https://trial.medpath.com/news/sonoma-biotherapeutics-reports-promising-phase-1-results-for-car-treg-therapy-in-refractory-rheumatoid-arthritis 2025-10-14T21:23:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sonoma-biotherapeutics-reports-promising-phase-1-results-for-car-treg-therapy-in-refractory-rheumatoid-arthritis 2025-10-14T21:23:36+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-ceo-confirms-no-drug-pricing-agreement-with-white-house-despite-ongoing-negotiations 2025-10-14T21:21:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/johnson-johnson-ceo-confirms-no-drug-pricing-agreement-with-white-house-despite-ongoing-negotiations 2025-10-14T21:21:38+00:00 hourly 0.9 https://trial.medpath.com/news/forlong-biotechnology-receives-milestone-payment-as-partner-s-fbody-r-fusion-protein-therapy-advances-to-ind-submission 2025-10-14T21:21:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/forlong-biotechnology-receives-milestone-payment-as-partner-s-fbody-r-fusion-protein-therapy-advances-to-ind-submission 2025-10-14T21:21:11+00:00 hourly 0.9 https://trial.medpath.com/news/bicara-therapeutics-receives-fda-breakthrough-therapy-designation-for-head-and-neck-cancer-treatment 2025-10-14T21:19:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bicara-therapeutics-receives-fda-breakthrough-therapy-designation-for-head-and-neck-cancer-treatment 2025-10-14T21:19:11+00:00 hourly 0.9 https://trial.medpath.com/news/start-opens-spain-s-first-pediatric-onco-hematology-clinical-research-unit-in-madrid 2025-10-14T21:18:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/start-opens-spain-s-first-pediatric-onco-hematology-clinical-research-unit-in-madrid 2025-10-14T21:18:50+00:00 hourly 0.9 https://trial.medpath.com/news/corventum-receives-fda-ind-clearance-for-cvt-130-first-in-class-cardioprotective-agent-for-anthracycline-chemotherapy 2025-10-14T21:18:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/corventum-receives-fda-ind-clearance-for-cvt-130-first-in-class-cardioprotective-agent-for-anthracycline-chemotherapy 2025-10-14T21:18:48+00:00 hourly 0.9 https://trial.medpath.com/news/crism-s-chemoseed-platform-shows-72-cancer-cell-kill-rate-in-prostate-cancer-preclinical-studies 2025-10-14T21:17:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/crism-s-chemoseed-platform-shows-72-cancer-cell-kill-rate-in-prostate-cancer-preclinical-studies 2025-10-14T21:17:36+00:00 hourly 0.9 https://trial.medpath.com/news/bayer-s-hyrnuo-receives-fda-approval-for-her2-mutated-non-small-cell-lung-cancer 2025-10-14T21:16:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bayer-s-hyrnuo-receives-fda-approval-for-her2-mutated-non-small-cell-lung-cancer 2025-10-14T21:16:19+00:00 hourly 0.9 https://trial.medpath.com/news/fuzzle-submits-novel-oral-device-for-fda-review-as-non-invasive-obesity-treatment 2025-10-14T21:16:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fuzzle-submits-novel-oral-device-for-fda-review-as-non-invasive-obesity-treatment 2025-10-14T21:16:04+00:00 hourly 0.9 https://trial.medpath.com/news/cd40-targeted-therapies-advance-toward-first-approval-by-2027-with-over-35-candidates-in-clinical-development 2025-10-14T21:15:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cd40-targeted-therapies-advance-toward-first-approval-by-2027-with-over-35-candidates-in-clinical-development 2025-10-14T21:15:04+00:00 hourly 0.9 https://trial.medpath.com/news/china-approves-world-s-first-functional-cure-drug-for-hepatitis-b 2025-10-14T17:31:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-approves-world-s-first-functional-cure-drug-for-hepatitis-b 2025-10-14T17:31:17+00:00 hourly 0.9 https://trial.medpath.com/news/krystal-biotech-receives-fda-platform-technology-designation-for-hsv-1-gene-therapy-vector 2025-10-14T17:31:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/krystal-biotech-receives-fda-platform-technology-designation-for-hsv-1-gene-therapy-vector 2025-10-14T17:31:11+00:00 hourly 0.9 https://trial.medpath.com/news/cabaletta-bio-appoints-steve-gavel-as-chief-commercial-officer-to-lead-car-t-therapy-launch 2025-10-14T17:30:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cabaletta-bio-appoints-steve-gavel-as-chief-commercial-officer-to-lead-car-t-therapy-launch 2025-10-14T17:30:39+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-to-spin-off-9-2-billion-orthopedics-business-as-depuy-synthes 2025-10-14T17:28:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/johnson-johnson-to-spin-off-9-2-billion-orthopedics-business-as-depuy-synthes 2025-10-14T17:28:56+00:00 hourly 0.9 https://trial.medpath.com/news/lunit-s-ai-platform-demonstrates-predictive-power-for-immunotherapy-response-across-multiple-cancer-types-at-esmo-2025 2025-10-14T17:25:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lunit-s-ai-platform-demonstrates-predictive-power-for-immunotherapy-response-across-multiple-cancer-types-at-esmo-2025 2025-10-14T17:25:20+00:00 hourly 0.9 https://trial.medpath.com/news/pilatus-biosciences-secures-global-patent-protection-for-cd36-targeted-immunotherapy-platform 2025-10-14T17:25:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pilatus-biosciences-secures-global-patent-protection-for-cd36-targeted-immunotherapy-platform 2025-10-14T17:25:15+00:00 hourly 0.9 https://trial.medpath.com/news/abalos-therapeutics-publishes-preclinical-data-for-novel-arenavirus-based-cancer-immunotherapy-abx-001 2025-10-14T17:25:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abalos-therapeutics-publishes-preclinical-data-for-novel-arenavirus-based-cancer-immunotherapy-abx-001 2025-10-14T17:25:12+00:00 hourly 0.9 https://trial.medpath.com/news/rivus-pharmaceuticals-to-present-phase-2a-mash-trial-data-for-novel-metabolic-accelerator-hu6-at-aasld-2025 2025-10-14T17:24:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rivus-pharmaceuticals-to-present-phase-2a-mash-trial-data-for-novel-metabolic-accelerator-hu6-at-aasld-2025 2025-10-14T17:24:24+00:00 hourly 0.9 https://trial.medpath.com/news/frontier-medicines-unveils-fmc-242-novel-pi3ka-ras-inhibitor-targeting-cancer-s-most-common-genetic-drivers 2025-10-14T17:24:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/frontier-medicines-unveils-fmc-242-novel-pi3ka-ras-inhibitor-targeting-cancer-s-most-common-genetic-drivers 2025-10-14T17:24:13+00:00 hourly 0.9 https://trial.medpath.com/news/tr1x-receives-fda-clearance-for-trx319-car-tr1-cell-therapy-in-progressive-multiple-sclerosis 2025-10-14T17:23:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tr1x-receives-fda-clearance-for-trx319-car-tr1-cell-therapy-in-progressive-multiple-sclerosis 2025-10-14T17:23:43+00:00 hourly 0.9 https://trial.medpath.com/news/swedish-researchers-launch-clinical-trial-testing-250-year-old-heart-drug-digitoxin-for-pancreatic-cancer-treatment 2025-10-14T17:23:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/swedish-researchers-launch-clinical-trial-testing-250-year-old-heart-drug-digitoxin-for-pancreatic-cancer-treatment 2025-10-14T17:23:24+00:00 hourly 0.9 https://trial.medpath.com/news/biocryst-acquires-astria-therapeutics-for-700-million-to-expand-hereditary-angioedema-treatment-portfolio 2025-10-14T17:23:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biocryst-acquires-astria-therapeutics-for-700-million-to-expand-hereditary-angioedema-treatment-portfolio 2025-10-14T17:23:16+00:00 hourly 0.9 https://trial.medpath.com/news/abk-biomedical-secures-35m-series-d-to-advance-eye90-microspheres-for-liver-cancer-treatment 2025-10-14T17:23:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abk-biomedical-secures-35m-series-d-to-advance-eye90-microspheres-for-liver-cancer-treatment 2025-10-14T17:23:13+00:00 hourly 0.9 https://trial.medpath.com/news/major-uk-study-reveals-risperidone-increases-stroke-risk-across-all-dementia-patient-groups 2025-10-14T17:23:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/major-uk-study-reveals-risperidone-increases-stroke-risk-across-all-dementia-patient-groups 2025-10-14T17:23:08+00:00 hourly 0.9 https://trial.medpath.com/news/lb-pharmaceuticals-strengthens-regulatory-leadership-with-james-rawls-appointment-ahead-of-lb-102-phase-3-trial 2025-10-14T17:22:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lb-pharmaceuticals-strengthens-regulatory-leadership-with-james-rawls-appointment-ahead-of-lb-102-phase-3-trial 2025-10-14T17:22:48+00:00 hourly 0.9 https://trial.medpath.com/news/genprex-s-reqorsa-gene-therapy-shows-79-tumor-reduction-in-alk-positive-lung-cancer-preclinical-study 2025-10-14T17:22:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genprex-s-reqorsa-gene-therapy-shows-79-tumor-reduction-in-alk-positive-lung-cancer-preclinical-study 2025-10-14T17:22:26+00:00 hourly 0.9 https://trial.medpath.com/news/brogidirsen-shows-sustained-motor-function-benefits-in-3-5-year-duchenne-muscular-dystrophy-trial 2025-10-14T17:22:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brogidirsen-shows-sustained-motor-function-benefits-in-3-5-year-duchenne-muscular-dystrophy-trial 2025-10-14T17:22:10+00:00 hourly 0.9 https://trial.medpath.com/news/candel-therapeutics-reports-breakthrough-data-for-can-3110-in-recurrent-glioblastoma-with-complete-pathological-response 2025-10-14T17:22:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/candel-therapeutics-reports-breakthrough-data-for-can-3110-in-recurrent-glioblastoma-with-complete-pathological-response 2025-10-14T17:22:08+00:00 hourly 0.9 https://trial.medpath.com/news/candel-therapeutics-secures-130-million-term-loan-to-advance-phase-3-nsclc-trial-and-prostate-cancer-commercialization 2025-10-14T17:22:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/candel-therapeutics-secures-130-million-term-loan-to-advance-phase-3-nsclc-trial-and-prostate-cancer-commercialization 2025-10-14T17:22:05+00:00 hourly 0.9 https://trial.medpath.com/news/caris-life-sciences-presents-six-multiomics-studies-at-esmo-2025-spanning-nine-cancer-types 2025-10-14T17:19:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/caris-life-sciences-presents-six-multiomics-studies-at-esmo-2025-spanning-nine-cancer-types 2025-10-14T17:19:50+00:00 hourly 0.9 https://trial.medpath.com/news/bvi-s-finevision-hp-trifocal-iol-receives-fda-approval-for-us-market-after-15-years-of-global-use 2025-10-14T17:18:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bvi-s-finevision-hp-trifocal-iol-receives-fda-approval-for-us-market-after-15-years-of-global-use 2025-10-14T17:18:00+00:00 hourly 0.9 https://trial.medpath.com/news/calcimedica-partners-with-telperian-to-deploy-ai-analytics-for-auxora-clinical-trial-optimization 2025-10-14T17:17:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/calcimedica-partners-with-telperian-to-deploy-ai-analytics-for-auxora-clinical-trial-optimization 2025-10-14T17:17:57+00:00 hourly 0.9 https://trial.medpath.com/news/cambridge-scientists-create-lab-grown-embryo-models-that-generate-human-blood-stem-cells 2025-10-14T17:17:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cambridge-scientists-create-lab-grown-embryo-models-that-generate-human-blood-stem-cells 2025-10-14T17:17:50+00:00 hourly 0.9 https://trial.medpath.com/news/cincinnati-children-s-develops-human-liver-organoid-platform-to-predict-immune-mediated-drug-toxicity 2025-10-14T17:17:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cincinnati-children-s-develops-human-liver-organoid-platform-to-predict-immune-mediated-drug-toxicity 2025-10-14T17:17:47+00:00 hourly 0.9 https://trial.medpath.com/news/neogenomics-showcases-radar-st-molecular-residual-disease-assay-at-esmo-congress-2025 2025-10-14T17:17:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neogenomics-showcases-radar-st-molecular-residual-disease-assay-at-esmo-congress-2025 2025-10-14T17:17:44+00:00 hourly 0.9 https://trial.medpath.com/news/tonix-pharmaceuticals-advances-tnx-1500-anti-cd40l-antibody-for-transplant-rejection-prevention 2025-10-14T17:17:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tonix-pharmaceuticals-advances-tnx-1500-anti-cd40l-antibody-for-transplant-rejection-prevention 2025-10-14T17:17:41+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-s-tukysa-shows-positive-results-in-phase-iii-maintenance-trial-for-her2-positive-breast-cancer 2025-10-14T17:16:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pfizer-s-tukysa-shows-positive-results-in-phase-iii-maintenance-trial-for-her2-positive-breast-cancer 2025-10-14T17:16:51+00:00 hourly 0.9 https://trial.medpath.com/news/quotient-sciences-and-biorasi-form-strategic-partnership-to-streamline-early-phase-clinical-trials 2025-10-14T17:16:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quotient-sciences-and-biorasi-form-strategic-partnership-to-streamline-early-phase-clinical-trials 2025-10-14T17:16:28+00:00 hourly 0.9 https://trial.medpath.com/news/researchers-develop-gene-signature-to-predict-immunotherapy-response-in-triple-negative-breast-cancer 2025-10-14T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/researchers-develop-gene-signature-to-predict-immunotherapy-response-in-triple-negative-breast-cancer 2025-10-14T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/dupilumab-reduces-severe-copd-exacerbations-regardless-of-cardiovascular-and-metabolic-comorbidities 2025-10-14T13:37:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dupilumab-reduces-severe-copd-exacerbations-regardless-of-cardiovascular-and-metabolic-comorbidities 2025-10-14T13:37:22+00:00 hourly 0.9 https://trial.medpath.com/news/takeda-expands-ai-drug-discovery-partnership-with-nabla-bio-in-1b-deal 2025-10-14T13:35:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/takeda-expands-ai-drug-discovery-partnership-with-nabla-bio-in-1b-deal 2025-10-14T13:35:32+00:00 hourly 0.9 https://trial.medpath.com/news/kailera-therapeutics-secures-600m-series-b-to-advance-obesity-drug-kai-9531-to-phase-3-trials 2025-10-14T13:34:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kailera-therapeutics-secures-600m-series-b-to-advance-obesity-drug-kai-9531-to-phase-3-trials 2025-10-14T13:34:26+00:00 hourly 0.9 https://trial.medpath.com/news/biontech-secures-german-regulatory-approval-for-1-25-billion-curevac-acquisition 2025-10-14T13:32:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biontech-secures-german-regulatory-approval-for-1-25-billion-curevac-acquisition 2025-10-14T13:32:26+00:00 hourly 0.9 https://trial.medpath.com/news/activist-investor-shah-capital-calls-for-novavax-sale-amid-covid-vaccine-market-share-struggles 2025-10-14T13:32:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/activist-investor-shah-capital-calls-for-novavax-sale-amid-covid-vaccine-market-share-struggles 2025-10-14T13:32:20+00:00 hourly 0.9 https://trial.medpath.com/news/aanastra-unveils-breakthrough-preclinical-data-for-in-vivo-car-t-and-p53-restoration-therapies 2025-10-14T13:31:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aanastra-unveils-breakthrough-preclinical-data-for-in-vivo-car-t-and-p53-restoration-therapies 2025-10-14T13:31:28+00:00 hourly 0.9 https://trial.medpath.com/news/cancervax-universal-cancer-platform-demonstrates-liver-sparing-properties-in-preclinical-studies 2025-10-14T13:31:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cancervax-universal-cancer-platform-demonstrates-liver-sparing-properties-in-preclinical-studies 2025-10-14T13:31:25+00:00 hourly 0.9 https://trial.medpath.com/news/clover-biopharmaceuticals-reports-positive-phase-i-data-for-first-in-class-rsv-hmpv-piv3-combination-vaccines 2025-10-14T13:30:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clover-biopharmaceuticals-reports-positive-phase-i-data-for-first-in-class-rsv-hmpv-piv3-combination-vaccines 2025-10-14T13:30:56+00:00 hourly 0.9 https://trial.medpath.com/news/actithera-licenses-breakthrough-covalent-chemistry-technologies-from-weizmann-institute-for-next-generation-radiopharmaceuticals 2025-10-14T13:30:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/actithera-licenses-breakthrough-covalent-chemistry-technologies-from-weizmann-institute-for-next-generation-radiopharmaceuticals 2025-10-14T13:30:53+00:00 hourly 0.9 https://trial.medpath.com/news/first-in-class-autotaxin-inhibitor-cambritaxestat-shows-promise-in-metastatic-pancreatic-cancer-phase-ib-trial 2025-10-14T13:29:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-in-class-autotaxin-inhibitor-cambritaxestat-shows-promise-in-metastatic-pancreatic-cancer-phase-ib-trial 2025-10-14T13:29:55+00:00 hourly 0.9 https://trial.medpath.com/news/quantro-therapeutics-extends-boehringer-ingelheim-partnership-for-transcription-factor-cancer-drug-discovery 2025-10-14T13:29:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quantro-therapeutics-extends-boehringer-ingelheim-partnership-for-transcription-factor-cancer-drug-discovery 2025-10-14T13:29:48+00:00 hourly 0.9 https://trial.medpath.com/news/phase-i-study-demonstrates-favorable-pharmacokinetics-and-safety-profile-of-capivasertib-in-chinese-patients-with-advanced-solid-tumors 2025-10-14T13:29:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-i-study-demonstrates-favorable-pharmacokinetics-and-safety-profile-of-capivasertib-in-chinese-patients-with-advanced-solid-tumors 2025-10-14T13:29:45+00:00 hourly 0.9 https://trial.medpath.com/news/ona-therapeutics-appoints-adc-development-veteran-dr-antoine-yver-as-board-chair-to-advance-breast-cancer-pipeline 2025-10-14T13:29:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ona-therapeutics-appoints-adc-development-veteran-dr-antoine-yver-as-board-chair-to-advance-breast-cancer-pipeline 2025-10-14T13:29:31+00:00 hourly 0.9 https://trial.medpath.com/news/apyx-medical-submits-fda-510-k-application-to-expand-ayon-body-contouring-system-for-power-liposuction 2025-10-14T13:28:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/apyx-medical-submits-fda-510-k-application-to-expand-ayon-body-contouring-system-for-power-liposuction 2025-10-14T13:28:46+00:00 hourly 0.9 https://trial.medpath.com/news/spago-nanomedical-s-177lu-sn201-shows-promising-tumor-uptake-in-phase-i-iia-trial 2025-10-14T13:28:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/spago-nanomedical-s-177lu-sn201-shows-promising-tumor-uptake-in-phase-i-iia-trial 2025-10-14T13:28:39+00:00 hourly 0.9 https://trial.medpath.com/news/innate-pharma-advances-lacutamab-toward-accelerated-approval-for-rare-t-cell-lymphomas 2025-10-14T09:34:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/innate-pharma-advances-lacutamab-toward-accelerated-approval-for-rare-t-cell-lymphomas 2025-10-14T09:34:26+00:00 hourly 0.9 https://trial.medpath.com/news/adc-therapeutics-secures-60-million-to-advance-zynlonta-commercialization-and-prepare-for-2027-relaunch 2025-10-14T09:32:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adc-therapeutics-secures-60-million-to-advance-zynlonta-commercialization-and-prepare-for-2027-relaunch 2025-10-14T09:32:04+00:00 hourly 0.9 https://trial.medpath.com/news/first-patient-enrolled-in-global-phase-3-trial-testing-novel-immune-modulatory-therapy-for-relapsed-follicular-lymphoma 2025-10-14T09:31:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-patient-enrolled-in-global-phase-3-trial-testing-novel-immune-modulatory-therapy-for-relapsed-follicular-lymphoma 2025-10-14T09:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/biosynth-experts-highlight-advanced-bioconjugation-strategies-for-enhanced-drug-development 2025-10-14T03:17:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biosynth-experts-highlight-advanced-bioconjugation-strategies-for-enhanced-drug-development 2025-10-14T03:17:13+00:00 hourly 0.9 https://trial.medpath.com/news/eilean-therapeutics-unveils-ze77-0273-novel-pan-egfr-inhibitor-for-drug-resistant-nsclc 2025-10-14T01:22:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eilean-therapeutics-unveils-ze77-0273-novel-pan-egfr-inhibitor-for-drug-resistant-nsclc 2025-10-14T01:22:02+00:00 hourly 0.9 https://trial.medpath.com/news/pyxis-oncology-unveils-translational-data-supporting-novel-adc-micvo-s-triple-action-mechanism-against-solid-tumors 2025-10-14T01:20:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pyxis-oncology-unveils-translational-data-supporting-novel-adc-micvo-s-triple-action-mechanism-against-solid-tumors 2025-10-14T01:20:45+00:00 hourly 0.9 https://trial.medpath.com/news/oticara-s-intranasal-steroid-cream-shows-significant-symptom-improvement-in-post-surgical-chronic-rhinosinusitis-phase-2-trial 2025-10-14T01:19:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oticara-s-intranasal-steroid-cream-shows-significant-symptom-improvement-in-post-surgical-chronic-rhinosinusitis-phase-2-trial 2025-10-14T01:19:14+00:00 hourly 0.9 https://trial.medpath.com/news/zentalis-pharmaceuticals-presents-four-azenosertib-studies-at-aacr-nci-eortc-conference 2025-10-14T01:19:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zentalis-pharmaceuticals-presents-four-azenosertib-studies-at-aacr-nci-eortc-conference 2025-10-14T01:19:11+00:00 hourly 0.9 https://trial.medpath.com/news/imdx-appoints-marketing-vp-to-spearhead-commercial-launch-of-transplant-rejection-diagnostic 2025-10-14T01:16:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/imdx-appoints-marketing-vp-to-spearhead-commercial-launch-of-transplant-rejection-diagnostic 2025-10-14T01:16:43+00:00 hourly 0.9 https://trial.medpath.com/news/repare-therapeutics-to-present-first-clinical-data-for-novel-plk4-inhibitor-rp-1664-at-aacr-conference 2025-10-13T21:28:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/repare-therapeutics-to-present-first-clinical-data-for-novel-plk4-inhibitor-rp-1664-at-aacr-conference 2025-10-13T21:28:52+00:00 hourly 0.9 https://trial.medpath.com/news/merus-petosemtamab-phase-2-data-selected-for-plenary-presentation-at-aacr-nci-eortc-conference 2025-10-13T21:28:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merus-petosemtamab-phase-2-data-selected-for-plenary-presentation-at-aacr-nci-eortc-conference 2025-10-13T21:28:06+00:00 hourly 0.9 https://trial.medpath.com/news/remix-therapeutics-to-present-phase-1-data-of-first-in-class-myb-rna-degrader-rem-422-for-adenoid-cystic-carcinoma-at-aacr-conference 2025-10-13T21:23:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/remix-therapeutics-to-present-phase-1-data-of-first-in-class-myb-rna-degrader-rem-422-for-adenoid-cystic-carcinoma-at-aacr-conference 2025-10-13T21:23:13+00:00 hourly 0.9 https://trial.medpath.com/news/merck-faces-patent-challenge-over-keytruda-qlex-as-ptab-institutes-seven-post-grant-reviews 2025-10-13T21:22:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-faces-patent-challenge-over-keytruda-qlex-as-ptab-institutes-seven-post-grant-reviews 2025-10-13T21:22:38+00:00 hourly 0.9 https://trial.medpath.com/news/lupin-invests-250-million-in-florida-manufacturing-facility-to-strengthen-us-respiratory-drug-supply 2025-10-13T21:22:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lupin-invests-250-million-in-florida-manufacturing-facility-to-strengthen-us-respiratory-drug-supply 2025-10-13T21:22:35+00:00 hourly 0.9 https://trial.medpath.com/news/mrna-therapy-restores-sperm-production-in-mouse-model-of-male-infertility 2025-10-13T21:22:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mrna-therapy-restores-sperm-production-in-mouse-model-of-male-infertility 2025-10-13T21:22:26+00:00 hourly 0.9 https://trial.medpath.com/news/rectal-spacers-reduce-prostate-cancer-treatment-failure-by-50-in-real-world-analysis 2025-10-13T21:21:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rectal-spacers-reduce-prostate-cancer-treatment-failure-by-50-in-real-world-analysis 2025-10-13T21:21:45+00:00 hourly 0.9 https://trial.medpath.com/news/rna-nanotherapeutics-develops-novel-approach-to-combat-tamoxifen-resistance-in-breast-cancer 2025-10-13T21:21:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rna-nanotherapeutics-develops-novel-approach-to-combat-tamoxifen-resistance-in-breast-cancer 2025-10-13T21:21:12+00:00 hourly 0.9 https://trial.medpath.com/news/zai-lab-s-dll3-targeted-adc-zocilurtatug-pelitecan-shows-promise-in-phase-1-small-cell-lung-cancer-trial 2025-10-13T21:20:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zai-lab-s-dll3-targeted-adc-zocilurtatug-pelitecan-shows-promise-in-phase-1-small-cell-lung-cancer-trial 2025-10-13T21:20:26+00:00 hourly 0.9 https://trial.medpath.com/news/accugenomics-and-1cell-ai-partner-to-enhance-liquid-biopsy-testing-accuracy-across-asia-with-u-s-expansion-plans 2025-10-13T21:19:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/accugenomics-and-1cell-ai-partner-to-enhance-liquid-biopsy-testing-accuracy-across-asia-with-u-s-expansion-plans 2025-10-13T21:19:24+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-fast-track-designation-to-epion-s-epismart-cross-linking-system-for-keratoconus-treatment 2025-10-13T21:19:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-fast-track-designation-to-epion-s-epismart-cross-linking-system-for-keratoconus-treatment 2025-10-13T21:19:06+00:00 hourly 0.9 https://trial.medpath.com/news/naya-therapeutics-partners-with-alpha-nuclide-to-advance-astatine-211-therapy-for-hepatocellular-carcinoma-in-china 2025-10-13T21:18:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/naya-therapeutics-partners-with-alpha-nuclide-to-advance-astatine-211-therapy-for-hepatocellular-carcinoma-in-china 2025-10-13T21:18:17+00:00 hourly 0.9 https://trial.medpath.com/news/neutrolis-to-present-early-human-proof-of-concept-data-for-novel-net-targeting-therapy-at-acr-2025 2025-10-13T19:15:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neutrolis-to-present-early-human-proof-of-concept-data-for-novel-net-targeting-therapy-at-acr-2025 2025-10-13T19:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/quanta-therapeutics-to-present-first-clinical-data-for-novel-kras-g12d-inhibitor-qtx3034-at-major-cancer-conference 2025-10-13T17:29:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quanta-therapeutics-to-present-first-clinical-data-for-novel-kras-g12d-inhibitor-qtx3034-at-major-cancer-conference 2025-10-13T17:29:53+00:00 hourly 0.9 https://trial.medpath.com/news/cstone-pharmaceuticals-presents-first-in-class-pd-1-vegf-ctla-4-trispecific-antibody-data-at-esmo-2025 2025-10-13T17:26:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cstone-pharmaceuticals-presents-first-in-class-pd-1-vegf-ctla-4-trispecific-antibody-data-at-esmo-2025 2025-10-13T17:26:35+00:00 hourly 0.9 https://trial.medpath.com/news/vasa-therapeutics-receives-fda-ind-clearance-for-vs-041-in-heart-failure-with-preserved-ejection-fraction 2025-10-13T17:25:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vasa-therapeutics-receives-fda-ind-clearance-for-vs-041-in-heart-failure-with-preserved-ejection-fraction 2025-10-13T17:25:41+00:00 hourly 0.9 https://trial.medpath.com/news/boehringer-ingelheim-to-begin-local-production-of-diabetes-drug-trajenta-in-shanghai-by-2028 2025-10-13T17:25:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/boehringer-ingelheim-to-begin-local-production-of-diabetes-drug-trajenta-in-shanghai-by-2028 2025-10-13T17:25:32+00:00 hourly 0.9 https://trial.medpath.com/news/general-oncology-to-present-phase-1-sharon-trial-results-for-brca-palb2-mutated-cancers-at-esmo-2025 2025-10-13T17:23:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/general-oncology-to-present-phase-1-sharon-trial-results-for-brca-palb2-mutated-cancers-at-esmo-2025 2025-10-13T17:23:48+00:00 hourly 0.9 https://trial.medpath.com/news/clearpoint-neuro-s-mr-guided-laser-therapy-shows-promise-for-brain-cancer-treatment-in-phase-i-ii-study 2025-10-13T17:22:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clearpoint-neuro-s-mr-guided-laser-therapy-shows-promise-for-brain-cancer-treatment-in-phase-i-ii-study 2025-10-13T17:22:43+00:00 hourly 0.9 https://trial.medpath.com/news/pantherx-rare-partners-with-chiesi-as-exclusive-distributor-for-oral-acromegaly-treatment-mycapssa 2025-10-13T17:21:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pantherx-rare-partners-with-chiesi-as-exclusive-distributor-for-oral-acromegaly-treatment-mycapssa 2025-10-13T17:21:57+00:00 hourly 0.9 https://trial.medpath.com/news/abeona-therapeutics-abo-503-gene-therapy-selected-for-fda-s-rare-disease-endpoint-advancement-pilot-program 2025-10-13T17:20:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abeona-therapeutics-abo-503-gene-therapy-selected-for-fda-s-rare-disease-endpoint-advancement-pilot-program 2025-10-13T17:20:30+00:00 hourly 0.9 https://trial.medpath.com/news/4dmt-secures-11-million-cf-foundation-investment-to-advance-gene-therapy-4d-710-into-phase-2-for-cystic-fibrosis 2025-10-13T17:19:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/4dmt-secures-11-million-cf-foundation-investment-to-advance-gene-therapy-4d-710-into-phase-2-for-cystic-fibrosis 2025-10-13T17:19:29+00:00 hourly 0.9 https://trial.medpath.com/news/yd-bio-partner-eg-biomed-secures-cap-accreditation-for-u-s-laboratory-strengthening-cancer-diagnostics-capabilities 2025-10-13T17:19:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/yd-bio-partner-eg-biomed-secures-cap-accreditation-for-u-s-laboratory-strengthening-cancer-diagnostics-capabilities 2025-10-13T17:19:27+00:00 hourly 0.9 https://trial.medpath.com/news/blacksmith-medicines-receives-fda-fast-track-and-qidp-designation-for-novel-antibiotic-fg-2101-targeting-gram-negative-superbugs 2025-10-13T17:19:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/blacksmith-medicines-receives-fda-fast-track-and-qidp-designation-for-novel-antibiotic-fg-2101-targeting-gram-negative-superbugs 2025-10-13T17:19:10+00:00 hourly 0.9 https://trial.medpath.com/news/nextbiomedical-initiates-u-s-pivotal-trial-for-nexsphere-f-microsphere-device-in-knee-osteoarthritis 2025-10-13T17:18:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nextbiomedical-initiates-u-s-pivotal-trial-for-nexsphere-f-microsphere-device-in-knee-osteoarthritis 2025-10-13T17:18:26+00:00 hourly 0.9 https://trial.medpath.com/news/infant-bacterial-therapeutics-advances-regulatory-submissions-for-ibp-9414-first-live-biotherapeutic-for-premature-infants 2025-10-13T17:17:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/infant-bacterial-therapeutics-advances-regulatory-submissions-for-ibp-9414-first-live-biotherapeutic-for-premature-infants 2025-10-13T17:17:29+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-strikes-most-favoured-nation-drug-pricing-deal-with-trump-administration 2025-10-13T17:17:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-strikes-most-favoured-nation-drug-pricing-deal-with-trump-administration 2025-10-13T17:17:27+00:00 hourly 0.9 https://trial.medpath.com/news/artivion-s-amds-device-shows-strong-malperfusion-resolution-rates-in-acute-aortic-dissection-trials 2025-10-13T17:17:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/artivion-s-amds-device-shows-strong-malperfusion-resolution-rates-in-acute-aortic-dissection-trials 2025-10-13T17:17:04+00:00 hourly 0.9 https://trial.medpath.com/news/excellergy-raises-70m-series-a-to-advance-novel-trifunctional-allergy-treatment-platform 2025-10-13T17:15:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/excellergy-raises-70m-series-a-to-advance-novel-trifunctional-allergy-treatment-platform 2025-10-13T17:15:56+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-expanded-rinvoq-label-for-ibd-treatment-allowing-earlier-use-when-tnf-blockers-inadvisable 2025-10-13T17:15:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-expanded-rinvoq-label-for-ibd-treatment-allowing-earlier-use-when-tnf-blockers-inadvisable 2025-10-13T17:15:49+00:00 hourly 0.9 https://trial.medpath.com/news/mettl14-emerges-as-key-regulator-of-tumor-immunity-and-immunotherapy-response 2025-10-13T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mettl14-emerges-as-key-regulator-of-tumor-immunity-and-immunotherapy-response 2025-10-13T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/sellas-life-sciences-reports-promising-preclinical-and-phase-2-data-for-cdk9-inhibitor-sls009-across-multiple-hematologic-malignancies 2025-10-13T13:29:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sellas-life-sciences-reports-promising-preclinical-and-phase-2-data-for-cdk9-inhibitor-sls009-across-multiple-hematologic-malignancies 2025-10-13T13:29:46+00:00 hourly 0.9 https://trial.medpath.com/news/artios-reports-first-clinical-data-for-dna-polymerase-theta-inhibitor-art6043-at-esmo-2025 2025-10-13T13:27:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/artios-reports-first-clinical-data-for-dna-polymerase-theta-inhibitor-art6043-at-esmo-2025 2025-10-13T13:27:41+00:00 hourly 0.9 https://trial.medpath.com/news/eib-and-european-commission-partner-with-biontech-for-africa-s-first-mrna-vaccine-manufacturing-facility-in-rwanda 2025-10-13T13:26:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eib-and-european-commission-partner-with-biontech-for-africa-s-first-mrna-vaccine-manufacturing-facility-in-rwanda 2025-10-13T13:26:19+00:00 hourly 0.9 https://trial.medpath.com/news/lupin-to-present-phase-1a-data-on-sting-agonist-lnp3693-at-esmo-2025 2025-10-13T13:22:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lupin-to-present-phase-1a-data-on-sting-agonist-lnp3693-at-esmo-2025 2025-10-13T13:22:50+00:00 hourly 0.9 https://trial.medpath.com/news/bristol-myers-squibb-and-lilly-showcase-major-oncology-data-at-esmo-2025 2025-10-13T13:21:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bristol-myers-squibb-and-lilly-showcase-major-oncology-data-at-esmo-2025 2025-10-13T13:21:13+00:00 hourly 0.9 https://trial.medpath.com/news/theolytics-advances-novel-oncolytic-immunotherapy-theo-260-in-phase-i-iia-ovarian-cancer-trial 2025-10-13T13:20:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/theolytics-advances-novel-oncolytic-immunotherapy-theo-260-in-phase-i-iia-ovarian-cancer-trial 2025-10-13T13:20:58+00:00 hourly 0.9 https://trial.medpath.com/news/new-report-analyzes-1775-clinical-stage-pharma-partnerships-from-2020-2025 2025-10-13T13:20:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-report-analyzes-1775-clinical-stage-pharma-partnerships-from-2020-2025 2025-10-13T13:20:52+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-rayner-s-rayone-emv-toric-iol-for-astigmatism-correction 2025-10-13T13:19:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-rayner-s-rayone-emv-toric-iol-for-astigmatism-correction 2025-10-13T13:19:56+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-s-adc-portfolio-shows-promising-results-across-multiple-solid-tumors-at-esmo-2025 2025-10-13T13:18:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbvie-s-adc-portfolio-shows-promising-results-across-multiple-solid-tumors-at-esmo-2025 2025-10-13T13:18:46+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-lasix-onyu-first-at-home-subcutaneous-furosemide-infusion-device-for-heart-failure 2025-10-13T13:18:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-lasix-onyu-first-at-home-subcutaneous-furosemide-infusion-device-for-heart-failure 2025-10-13T13:18:34+00:00 hourly 0.9 https://trial.medpath.com/news/revir-therapeutics-secures-fda-orphan-drug-designation-for-rtx-117-in-charcot-marie-tooth-disease 2025-10-13T13:18:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/revir-therapeutics-secures-fda-orphan-drug-designation-for-rtx-117-in-charcot-marie-tooth-disease 2025-10-13T13:18:12+00:00 hourly 0.9 https://trial.medpath.com/news/lts-acquires-renaissance-lakewood-to-expand-cdmo-capabilities-in-nasal-drug-delivery 2025-10-13T13:18:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lts-acquires-renaissance-lakewood-to-expand-cdmo-capabilities-in-nasal-drug-delivery 2025-10-13T13:18:05+00:00 hourly 0.9 https://trial.medpath.com/news/gc-biopharma-partners-with-curevo-vaccine-to-manufacture-next-generation-shingles-vaccine-with-improved-tolerability 2025-10-13T09:20:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gc-biopharma-partners-with-curevo-vaccine-to-manufacture-next-generation-shingles-vaccine-with-improved-tolerability 2025-10-13T09:20:10+00:00 hourly 0.9 https://trial.medpath.com/news/takeda-completes-370-million-global-manufacturing-expansion-for-rare-disease-therapies 2025-10-13T09:19:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/takeda-completes-370-million-global-manufacturing-expansion-for-rare-disease-therapies 2025-10-13T09:19:40+00:00 hourly 0.9 https://trial.medpath.com/news/annji-s-aj201-shows-clinical-promise-for-kennedy-s-disease-in-phase-2a-trial 2025-10-13T09:17:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/annji-s-aj201-shows-clinical-promise-for-kennedy-s-disease-in-phase-2a-trial 2025-10-13T09:17:59+00:00 hourly 0.9 https://trial.medpath.com/news/avacta-develops-first-dual-payload-peptide-drug-conjugate-platform-for-cancer-combination-therapy 2025-10-13T09:17:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avacta-develops-first-dual-payload-peptide-drug-conjugate-platform-for-cancer-combination-therapy 2025-10-13T09:17:31+00:00 hourly 0.9 https://trial.medpath.com/news/cspc-pharmaceutical-s-syh2070-sirna-injection-receives-dual-fda-and-nmpa-approval-for-lipid-disorder-trials 2025-10-13T09:16:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cspc-pharmaceutical-s-syh2070-sirna-injection-receives-dual-fda-and-nmpa-approval-for-lipid-disorder-trials 2025-10-13T09:16:57+00:00 hourly 0.9 https://trial.medpath.com/news/ucb-s-pyrimidine-nucleoside-therapy-shows-95-reduction-in-death-risk-for-ultra-rare-tk2-deficiency 2025-10-13T09:16:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ucb-s-pyrimidine-nucleoside-therapy-shows-95-reduction-in-death-risk-for-ultra-rare-tk2-deficiency 2025-10-13T09:16:47+00:00 hourly 0.9 https://trial.medpath.com/news/dublin-biotech-meta-flux-raises-eur1-8m-to-enhance-drug-development-accuracy-with-ai-platform 2025-10-13T09:16:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dublin-biotech-meta-flux-raises-eur1-8m-to-enhance-drug-development-accuracy-with-ai-platform 2025-10-13T09:16:44+00:00 hourly 0.9 https://trial.medpath.com/news/ascendis-pharma-s-weekly-cnp-therapy-challenges-biomarin-s-daily-voxzogo-in-achondroplasia-market 2025-10-13T05:18:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ascendis-pharma-s-weekly-cnp-therapy-challenges-biomarin-s-daily-voxzogo-in-achondroplasia-market 2025-10-13T05:18:13+00:00 hourly 0.9 https://trial.medpath.com/news/context-therapeutics-advances-two-bispecific-t-cell-engagers-with-promising-early-clinical-and-preclinical-data-at-sitc-2025 2025-10-13T05:16:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/context-therapeutics-advances-two-bispecific-t-cell-engagers-with-promising-early-clinical-and-preclinical-data-at-sitc-2025 2025-10-13T05:16:48+00:00 hourly 0.9 https://trial.medpath.com/news/two-decade-analysis-reveals-high-discontinuation-rates-in-chinese-pediatric-drug-trials 2025-10-13T05:15:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/two-decade-analysis-reveals-high-discontinuation-rates-in-chinese-pediatric-drug-trials 2025-10-13T05:15:30+00:00 hourly 0.9 https://trial.medpath.com/news/proteomic-analysis-reveals-molecular-changes-following-anti-vegf-therapy-in-age-related-macular-degeneration 2025-10-13T01:18:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/proteomic-analysis-reveals-molecular-changes-following-anti-vegf-therapy-in-age-related-macular-degeneration 2025-10-13T01:18:01+00:00 hourly 0.9 https://trial.medpath.com/news/nouscom-s-nous-209-shows-promise-in-anti-pd-1-resistant-msi-h-colorectal-cancer 2025-10-13T01:16:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nouscom-s-nous-209-shows-promise-in-anti-pd-1-resistant-msi-h-colorectal-cancer 2025-10-13T01:16:43+00:00 hourly 0.9 https://trial.medpath.com/news/natera-s-signatera-mrd-test-shows-promise-in-guiding-bladder-cancer-treatment-at-esmo-2025 2025-10-13T01:16:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/natera-s-signatera-mrd-test-shows-promise-in-guiding-bladder-cancer-treatment-at-esmo-2025 2025-10-13T01:16:31+00:00 hourly 0.9 https://trial.medpath.com/news/advancell-reports-first-clinical-data-for-lead-212-based-psma-therapy-in-prostate-cancer-at-esmo-2025 2025-10-13T01:15:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/advancell-reports-first-clinical-data-for-lead-212-based-psma-therapy-in-prostate-cancer-at-esmo-2025 2025-10-13T01:15:51+00:00 hourly 0.9 https://trial.medpath.com/news/punjab-health-department-suspends-eight-iv-fluids-and-antibiotics-following-adverse-drug-reactions 2025-10-12T21:20:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/punjab-health-department-suspends-eight-iv-fluids-and-antibiotics-following-adverse-drug-reactions 2025-10-12T21:20:38+00:00 hourly 0.9 https://trial.medpath.com/news/nafdac-partners-with-nigeria-natural-medicine-agency-to-advance-herbal-drug-clinical-trials 2025-10-12T21:19:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nafdac-partners-with-nigeria-natural-medicine-agency-to-advance-herbal-drug-clinical-trials 2025-10-12T21:19:38+00:00 hourly 0.9 https://trial.medpath.com/news/marstacimab-demonstrates-superior-efficacy-in-phase-3-basis-trial-for-hemophilia-a-and-b-patients 2025-10-12T17:16:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/marstacimab-demonstrates-superior-efficacy-in-phase-3-basis-trial-for-hemophilia-a-and-b-patients 2025-10-12T17:16:06+00:00 hourly 0.9 https://trial.medpath.com/news/cefiderocol-shows-non-inferiority-to-standard-therapy-in-gram-negative-bloodstream-infections 2025-10-12T17:15:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cefiderocol-shows-non-inferiority-to-standard-therapy-in-gram-negative-bloodstream-infections 2025-10-12T17:15:30+00:00 hourly 0.9 https://trial.medpath.com/news/regeneron-s-db-oto-gene-therapy-restores-hearing-in-11-of-12-children-with-genetic-hearing-loss 2025-10-12T17:15:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regeneron-s-db-oto-gene-therapy-restores-hearing-in-11-of-12-children-with-genetic-hearing-loss 2025-10-12T17:15:02+00:00 hourly 0.9 https://trial.medpath.com/news/dual-immune-checkpoint-blockade-shows-promising-results-across-multiple-cancer-types 2025-10-12T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dual-immune-checkpoint-blockade-shows-promising-results-across-multiple-cancer-types 2025-10-12T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/hybrid-deep-learning-framework-achieves-85-accuracy-in-skin-lesion-diagnosis-with-enhanced-explainability 2025-10-12T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hybrid-deep-learning-framework-achieves-85-accuracy-in-skin-lesion-diagnosis-with-enhanced-explainability 2025-10-12T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/precision-biosciences-arcus-gene-editing-platform-achieves-85-efficiency-in-t-cells-advances-hepatitis-b-and-dmd-programs 2025-10-12T13:18:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/precision-biosciences-arcus-gene-editing-platform-achieves-85-efficiency-in-t-cells-advances-hepatitis-b-and-dmd-programs 2025-10-12T13:18:53+00:00 hourly 0.9 https://trial.medpath.com/news/indian-regulatory-committee-requests-protocol-revisions-for-enzene-s-nivolumab-biosimilar-phase-iii-trial 2025-10-12T09:17:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/indian-regulatory-committee-requests-protocol-revisions-for-enzene-s-nivolumab-biosimilar-phase-iii-trial 2025-10-12T09:17:23+00:00 hourly 0.9 https://trial.medpath.com/news/hmc-partners-with-abbvie-to-launch-clinical-research-training-program-in-qatar 2025-10-12T05:17:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hmc-partners-with-abbvie-to-launch-clinical-research-training-program-in-qatar 2025-10-12T05:17:38+00:00 hourly 0.9 https://trial.medpath.com/news/ligand-pharmaceuticals-gains-fda-approval-for-lasix-onyu-heart-failure-device-driving-46-share-price-surge 2025-10-12T05:17:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ligand-pharmaceuticals-gains-fda-approval-for-lasix-onyu-heart-failure-device-driving-46-share-price-surge 2025-10-12T05:17:36+00:00 hourly 0.9 https://trial.medpath.com/news/fda-authorizes-altria-s-on-plus-nicotine-pouches-under-new-pilot-program 2025-10-12T05:17:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-authorizes-altria-s-on-plus-nicotine-pouches-under-new-pilot-program 2025-10-12T05:17:33+00:00 hourly 0.9 https://trial.medpath.com/news/nasus-pharma-partners-with-aptar-to-accelerate-ns002-intranasal-epinephrine-development 2025-10-12T01:17:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nasus-pharma-partners-with-aptar-to-accelerate-ns002-intranasal-epinephrine-development 2025-10-12T01:17:47+00:00 hourly 0.9 https://trial.medpath.com/news/multi-cancer-blood-test-shows-62-accuracy-in-major-us-trial-raising-hopes-for-early-detection-revolution 2025-10-11T21:25:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/multi-cancer-blood-test-shows-62-accuracy-in-major-us-trial-raising-hopes-for-early-detection-revolution 2025-10-11T21:25:08+00:00 hourly 0.9 https://trial.medpath.com/news/fda-orphan-drug-director-sandra-retzky-reassigned-amid-inflation-reduction-act-policy-changes 2025-10-11T21:22:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-orphan-drug-director-sandra-retzky-reassigned-amid-inflation-reduction-act-policy-changes 2025-10-11T21:22:55+00:00 hourly 0.9 https://trial.medpath.com/news/sandstone-medical-launches-patent-protected-hexagonal-hub-pen-needles-in-turkey-for-enhanced-diabetes-care 2025-10-11T17:22:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sandstone-medical-launches-patent-protected-hexagonal-hub-pen-needles-in-turkey-for-enhanced-diabetes-care 2025-10-11T17:22:53+00:00 hourly 0.9 https://trial.medpath.com/news/vimkunya-chikungunya-vaccine-shows-consistent-safety-profile-in-early-real-world-use 2025-10-11T17:21:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vimkunya-chikungunya-vaccine-shows-consistent-safety-profile-in-early-real-world-use 2025-10-11T17:21:58+00:00 hourly 0.9 https://trial.medpath.com/news/biokin-pharmaceutical-receives-nmpa-approval-for-first-in-class-radiopharmaceutical-177lu-bl-arc001 2025-10-11T17:21:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biokin-pharmaceutical-receives-nmpa-approval-for-first-in-class-radiopharmaceutical-177lu-bl-arc001 2025-10-11T17:21:52+00:00 hourly 0.9 https://trial.medpath.com/news/apogee-therapeutics-raises-345-million-to-advance-inflammatory-disease-pipeline 2025-10-11T17:21:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/apogee-therapeutics-raises-345-million-to-advance-inflammatory-disease-pipeline 2025-10-11T17:21:45+00:00 hourly 0.9 https://trial.medpath.com/news/singapore-opens-new-clinical-trial-centre-for-precision-geromedicine-at-nus-medicine 2025-10-11T17:20:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/singapore-opens-new-clinical-trial-centre-for-precision-geromedicine-at-nus-medicine 2025-10-11T17:20:48+00:00 hourly 0.9 https://trial.medpath.com/news/protagonist-therapeutics-stock-surges-32-following-positive-icotrokinra-phase-3-results-and-strategic-partnerships 2025-10-11T13:23:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/protagonist-therapeutics-stock-surges-32-following-positive-icotrokinra-phase-3-results-and-strategic-partnerships 2025-10-11T13:23:33+00:00 hourly 0.9 https://trial.medpath.com/news/global-study-links-hair-loss-drug-finasteride-to-increased-suicide-risk-and-depression 2025-10-11T13:22:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-study-links-hair-loss-drug-finasteride-to-increased-suicide-risk-and-depression 2025-10-11T13:22:54+00:00 hourly 0.9 https://trial.medpath.com/news/fda-adds-boxed-warning-to-carvykti-for-fatal-gastrointestinal-complications 2025-10-11T05:28:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-adds-boxed-warning-to-carvykti-for-fatal-gastrointestinal-complications 2025-10-11T05:28:30+00:00 hourly 0.9 https://trial.medpath.com/news/large-real-world-study-confirms-long-term-benefits-of-allergen-immunotherapy-in-pediatric-allergic-rhinitis 2025-10-11T01:18:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/large-real-world-study-confirms-long-term-benefits-of-allergen-immunotherapy-in-pediatric-allergic-rhinitis 2025-10-11T01:18:30+00:00 hourly 0.9 https://trial.medpath.com/news/ai-technology-group-acquires-avm-biotechnology-to-advance-novel-cancer-immunotherapy-avm0703 2025-10-11T01:17:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-technology-group-acquires-avm-biotechnology-to-advance-novel-cancer-immunotherapy-avm0703 2025-10-11T01:17:28+00:00 hourly 0.9 https://trial.medpath.com/news/bluejay-diagnostics-raises-4-5-million-to-advance-fda-approval-for-rapid-sepsis-diagnostic-test 2025-10-11T01:16:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bluejay-diagnostics-raises-4-5-million-to-advance-fda-approval-for-rapid-sepsis-diagnostic-test 2025-10-11T01:16:59+00:00 hourly 0.9 https://trial.medpath.com/news/bridgebio-s-ribitol-shows-promise-in-phase-3-trial-for-rare-limb-girdle-muscular-dystrophy 2025-10-11T01:15:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bridgebio-s-ribitol-shows-promise-in-phase-3-trial-for-rare-limb-girdle-muscular-dystrophy 2025-10-11T01:15:52+00:00 hourly 0.9 https://trial.medpath.com/news/gates-foundation-and-paho-explore-strategies-to-expand-weight-loss-drug-access-in-lower-income-countries 2025-10-10T21:25:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gates-foundation-and-paho-explore-strategies-to-expand-weight-loss-drug-access-in-lower-income-countries 2025-10-10T21:25:09+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-in-acquisition-talks-with-protagonist-therapeutics-following-positive-ulcerative-colitis-trial-results 2025-10-10T21:22:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/johnson-johnson-in-acquisition-talks-with-protagonist-therapeutics-following-positive-ulcerative-colitis-trial-results 2025-10-10T21:22:04+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-exits-cell-therapy-terminates-type-1-diabetes-cure-program 2025-10-10T21:21:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novo-nordisk-exits-cell-therapy-terminates-type-1-diabetes-cure-program 2025-10-10T21:21:58+00:00 hourly 0.9 https://trial.medpath.com/news/triple-drug-combination-triggers-immune-activating-cell-death-to-eliminate-leukemia-in-preclinical-models 2025-10-10T21:20:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/triple-drug-combination-triggers-immune-activating-cell-death-to-eliminate-leukemia-in-preclinical-models 2025-10-10T21:20:29+00:00 hourly 0.9 https://trial.medpath.com/news/sareum-halts-sdc-1801-toxicology-study-due-to-animal-welfare-concerns-phase-2-psoriasis-trial-delayed 2025-10-10T21:19:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sareum-halts-sdc-1801-toxicology-study-due-to-animal-welfare-concerns-phase-2-psoriasis-trial-delayed 2025-10-10T21:19:33+00:00 hourly 0.9 https://trial.medpath.com/news/spanish-researchers-develop-peptide-nanotube-system-to-overcome-doxorubicin-resistance-in-cancer 2025-10-10T21:17:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/spanish-researchers-develop-peptide-nanotube-system-to-overcome-doxorubicin-resistance-in-cancer 2025-10-10T21:17:14+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-in-advanced-acquisition-talks-with-protagonist-therapeutics-for-4-2-billion-deal 2025-10-10T17:27:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/johnson-johnson-in-advanced-acquisition-talks-with-protagonist-therapeutics-for-4-2-billion-deal 2025-10-10T17:27:07+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-and-astrazeneca-emerge-as-leading-candidates-for-next-trump-administration-drug-pricing-deal 2025-10-10T17:23:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eli-lilly-and-astrazeneca-emerge-as-leading-candidates-for-next-trump-administration-drug-pricing-deal 2025-10-10T17:23:55+00:00 hourly 0.9 https://trial.medpath.com/news/chugai-licenses-roche-s-ct-388-dual-glp-1-gip-receptor-agonist-for-japan-market 2025-10-10T17:21:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chugai-licenses-roche-s-ct-388-dual-glp-1-gip-receptor-agonist-for-japan-market 2025-10-10T17:21:24+00:00 hourly 0.9 https://trial.medpath.com/news/amplifi-vascular-s-novel-vein-dilation-system-shows-promise-for-improving-hemodialysis-access-in-first-in-human-study 2025-10-10T17:20:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amplifi-vascular-s-novel-vein-dilation-system-shows-promise-for-improving-hemodialysis-access-in-first-in-human-study 2025-10-10T17:20:57+00:00 hourly 0.9 https://trial.medpath.com/news/gene-therapy-shows-promise-for-syngap1-related-brain-disorders-in-preclinical-study 2025-10-10T17:20:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gene-therapy-shows-promise-for-syngap1-related-brain-disorders-in-preclinical-study 2025-10-10T17:20:55+00:00 hourly 0.9 https://trial.medpath.com/news/genflow-biosciences-reports-positive-safety-data-from-second-administration-of-sirt6-gene-therapy-in-elderly-dogs 2025-10-10T17:19:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genflow-biosciences-reports-positive-safety-data-from-second-administration-of-sirt6-gene-therapy-in-elderly-dogs 2025-10-10T17:19:40+00:00 hourly 0.9 https://trial.medpath.com/news/neprilysin-gene-transfer-shows-promise-in-reducing-alzheimer-s-amyloid-beta-levels-and-improving-cognition 2025-10-10T17:19:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neprilysin-gene-transfer-shows-promise-in-reducing-alzheimer-s-amyloid-beta-levels-and-improving-cognition 2025-10-10T17:19:35+00:00 hourly 0.9 https://trial.medpath.com/news/orion-corporation-s-odm-105-fails-phase-2-insomnia-trial-as-company-pivots-to-oncology-focus 2025-10-10T17:18:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/orion-corporation-s-odm-105-fails-phase-2-insomnia-trial-as-company-pivots-to-oncology-focus 2025-10-10T17:18:34+00:00 hourly 0.9 https://trial.medpath.com/news/askbio-reports-positive-interim-safety-data-for-ab-1003-gene-therapy-in-rare-muscular-dystrophy-trial 2025-10-10T17:18:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/askbio-reports-positive-interim-safety-data-for-ab-1003-gene-therapy-in-rare-muscular-dystrophy-trial 2025-10-10T17:18:22+00:00 hourly 0.9 https://trial.medpath.com/news/bristol-myers-squibb-acquires-orbital-therapeutics-for-1-5-billion-to-advance-in-vivo-car-t-cell-therapy 2025-10-10T17:18:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bristol-myers-squibb-acquires-orbital-therapeutics-for-1-5-billion-to-advance-in-vivo-car-t-cell-therapy 2025-10-10T17:18:10+00:00 hourly 0.9 https://trial.medpath.com/news/senate-passes-biosecure-act-to-restrict-u-s-pharmaceutical-partnerships-with-chinese-companies 2025-10-10T17:18:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/senate-passes-biosecure-act-to-restrict-u-s-pharmaceutical-partnerships-with-chinese-companies 2025-10-10T17:18:08+00:00 hourly 0.9 https://trial.medpath.com/news/evommune-files-for-100m-ipo-to-advance-novel-mrgprx2-targeting-drug-for-chronic-urticaria 2025-10-10T17:17:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/evommune-files-for-100m-ipo-to-advance-novel-mrgprx2-targeting-drug-for-chronic-urticaria 2025-10-10T17:17:39+00:00 hourly 0.9 https://trial.medpath.com/news/cd276-emerges-as-promising-cancer-target-with-major-licensing-deals-and-fda-breakthrough-designations 2025-10-10T17:15:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cd276-emerges-as-promising-cancer-target-with-major-licensing-deals-and-fda-breakthrough-designations 2025-10-10T17:15:50+00:00 hourly 0.9 https://trial.medpath.com/news/wu-yifang-appointed-chairman-of-everest-medicines-as-company-advances-mrna-cancer-vaccine-platform 2025-10-10T13:18:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wu-yifang-appointed-chairman-of-everest-medicines-as-company-advances-mrna-cancer-vaccine-platform 2025-10-10T13:18:21+00:00 hourly 0.9 https://trial.medpath.com/news/jubilant-hollisterstier-launches-132-million-sterile-injectable-manufacturing-line-in-washington 2025-10-10T13:15:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jubilant-hollisterstier-launches-132-million-sterile-injectable-manufacturing-line-in-washington 2025-10-10T13:15:53+00:00 hourly 0.9 https://trial.medpath.com/news/renalys-completes-primary-endpoint-data-collection-for-sparsentan-phase-iii-trial-in-japanese-iga-nephropathy-patients 2025-10-10T09:16:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/renalys-completes-primary-endpoint-data-collection-for-sparsentan-phase-iii-trial-in-japanese-iga-nephropathy-patients 2025-10-10T09:16:31+00:00 hourly 0.9 https://trial.medpath.com/news/pv-10-shows-promise-as-novel-sting-pathway-vaccine-adjuvant-in-university-of-calgary-research 2025-10-10T01:23:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pv-10-shows-promise-as-novel-sting-pathway-vaccine-adjuvant-in-university-of-calgary-research 2025-10-10T01:23:03+00:00 hourly 0.9 https://trial.medpath.com/news/parse-biosciences-wins-patent-invalidation-case-against-10x-genomics-in-single-cell-sequencing-dispute 2025-10-10T01:18:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/parse-biosciences-wins-patent-invalidation-case-against-10x-genomics-in-single-cell-sequencing-dispute 2025-10-10T01:18:25+00:00 hourly 0.9 https://trial.medpath.com/news/shuttle-pharmaceuticals-signs-10-million-letter-of-intent-to-acquire-ai-drug-discovery-platform-molecule-ai 2025-10-10T01:17:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/shuttle-pharmaceuticals-signs-10-million-letter-of-intent-to-acquire-ai-drug-discovery-platform-molecule-ai 2025-10-10T01:17:14+00:00 hourly 0.9 https://trial.medpath.com/news/long-term-survival-data-reinforce-parp-inhibitor-benefits-in-brca-mutated-ovarian-cancer 2025-10-10T01:17:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/long-term-survival-data-reinforce-parp-inhibitor-benefits-in-brca-mutated-ovarian-cancer 2025-10-10T01:17:08+00:00 hourly 0.9 https://trial.medpath.com/news/arcadia-medicine-receives-fda-approval-for-clinical-trials-of-safer-mdma-formulation-am-1002 2025-10-10T01:15:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arcadia-medicine-receives-fda-approval-for-clinical-trials-of-safer-mdma-formulation-am-1002 2025-10-10T01:15:53+00:00 hourly 0.9 https://trial.medpath.com/news/nurix-therapeutics-advances-bexobrutideg-toward-pivotal-cll-trials-with-strong-phase-1-data 2025-10-09T21:23:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nurix-therapeutics-advances-bexobrutideg-toward-pivotal-cll-trials-with-strong-phase-1-data 2025-10-09T21:23:41+00:00 hourly 0.9 https://trial.medpath.com/news/expedition-therapeutics-secures-165-million-series-a-to-advance-first-in-class-dpp1-inhibitor-for-copd 2025-10-09T21:22:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/expedition-therapeutics-secures-165-million-series-a-to-advance-first-in-class-dpp1-inhibitor-for-copd 2025-10-09T21:22:28+00:00 hourly 0.9 https://trial.medpath.com/news/novel-tor-inhibitor-rapalink-1-extends-lifespan-through-gut-bacteria-enzyme-pathway 2025-10-09T21:21:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-tor-inhibitor-rapalink-1-extends-lifespan-through-gut-bacteria-enzyme-pathway 2025-10-09T21:21:47+00:00 hourly 0.9 https://trial.medpath.com/news/acurx-pharmaceuticals-secures-australian-patent-for-novel-dna-polymerase-iiic-inhibitor-antibiotics 2025-10-09T21:21:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/acurx-pharmaceuticals-secures-australian-patent-for-novel-dna-polymerase-iiic-inhibitor-antibiotics 2025-10-09T21:21:03+00:00 hourly 0.9 https://trial.medpath.com/news/cabaletta-bio-s-car-t-therapy-shows-promise-without-preconditioning-in-pemphigus-vulgaris-trial 2025-10-09T21:20:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cabaletta-bio-s-car-t-therapy-shows-promise-without-preconditioning-in-pemphigus-vulgaris-trial 2025-10-09T21:20:13+00:00 hourly 0.9 https://trial.medpath.com/news/phase-2-trial-of-inhaled-il-15-immunotherapy-halted-after-worse-outcomes-in-canine-osteosarcoma 2025-10-09T21:16:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-2-trial-of-inhaled-il-15-immunotherapy-halted-after-worse-outcomes-in-canine-osteosarcoma 2025-10-09T21:16:34+00:00 hourly 0.9 https://trial.medpath.com/news/novel-ras-pi3k-inhibitor-enters-clinical-trials-targeting-cancer-growth-without-metabolic-side-effects 2025-10-09T21:15:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-ras-pi3k-inhibitor-enters-clinical-trials-targeting-cancer-growth-without-metabolic-side-effects 2025-10-09T21:15:37+00:00 hourly 0.9 https://trial.medpath.com/news/sq-innovation-secures-series-b-funding-following-fda-approval-of-subcutaneous-furosemide-for-heart-failure 2025-10-09T17:26:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sq-innovation-secures-series-b-funding-following-fda-approval-of-subcutaneous-furosemide-for-heart-failure 2025-10-09T17:26:57+00:00 hourly 0.9 https://trial.medpath.com/news/cdsco-initiates-review-of-india-s-new-drug-approval-framework-to-address-first-mover-disadvantage 2025-10-09T17:26:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cdsco-initiates-review-of-india-s-new-drug-approval-framework-to-address-first-mover-disadvantage 2025-10-09T17:26:00+00:00 hourly 0.9 https://trial.medpath.com/news/apogee-therapeutics-surges-19-7-on-positive-apg333-phase-1-data-and-345-million-funding 2025-10-09T17:26:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/apogee-therapeutics-surges-19-7-on-positive-apg333-phase-1-data-and-345-million-funding 2025-10-09T17:26:00+00:00 hourly 0.9 https://trial.medpath.com/news/lexaria-bioscience-expands-drug-delivery-platform-development-with-4m-funding-and-strategic-advisory-partnership 2025-10-09T17:25:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lexaria-bioscience-expands-drug-delivery-platform-development-with-4m-funding-and-strategic-advisory-partnership 2025-10-09T17:25:36+00:00 hourly 0.9 https://trial.medpath.com/news/orexa-s-ore-001-shows-significant-promise-in-preventing-post-operative-ileus-in-phase-2-trial 2025-10-09T17:23:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/orexa-s-ore-001-shows-significant-promise-in-preventing-post-operative-ileus-in-phase-2-trial 2025-10-09T17:23:24+00:00 hourly 0.9 https://trial.medpath.com/news/telomir-1-demonstrates-selective-killing-of-triple-negative-breast-cancer-cells-through-iron-dependent-mechanism 2025-10-09T17:22:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/telomir-1-demonstrates-selective-killing-of-triple-negative-breast-cancer-cells-through-iron-dependent-mechanism 2025-10-09T17:22:36+00:00 hourly 0.9 https://trial.medpath.com/news/delhi-high-court-clears-path-for-generic-risdiplam-launch-enabling-97-price-reduction-for-rare-disease-treatment 2025-10-09T17:21:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/delhi-high-court-clears-path-for-generic-risdiplam-launch-enabling-97-price-reduction-for-rare-disease-treatment 2025-10-09T17:21:50+00:00 hourly 0.9 https://trial.medpath.com/news/milestone-pharmaceuticals-to-present-etripamil-psvt-data-at-aha-scientific-sessions-2025 2025-10-09T17:21:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/milestone-pharmaceuticals-to-present-etripamil-psvt-data-at-aha-scientific-sessions-2025 2025-10-09T17:21:36+00:00 hourly 0.9 https://trial.medpath.com/news/cognivia-launches-ai-powered-dashboard-to-predict-clinical-trial-dropout-and-placebo-response-in-real-time 2025-10-09T17:21:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cognivia-launches-ai-powered-dashboard-to-predict-clinical-trial-dropout-and-placebo-response-in-real-time 2025-10-09T17:21:30+00:00 hourly 0.9 https://trial.medpath.com/news/transcode-therapeutics-acquires-polynoma-in-25-million-deal-to-advance-phase-3-ready-melanoma-vaccine 2025-10-09T17:21:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/transcode-therapeutics-acquires-polynoma-in-25-million-deal-to-advance-phase-3-ready-melanoma-vaccine 2025-10-09T17:21:04+00:00 hourly 0.9 https://trial.medpath.com/news/henlius-hansizhuang-achieves-breakthrough-in-gastric-cancer-trial-enabling-world-first-chemotherapy-free-adjuvant-approach 2025-10-09T17:18:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/henlius-hansizhuang-achieves-breakthrough-in-gastric-cancer-trial-enabling-world-first-chemotherapy-free-adjuvant-approach 2025-10-09T17:18:13+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-acquires-akero-therapeutics-for-up-to-5-2-billion-to-expand-mash-treatment-portfolio 2025-10-09T17:18:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novo-nordisk-acquires-akero-therapeutics-for-up-to-5-2-billion-to-expand-mash-treatment-portfolio 2025-10-09T17:18:00+00:00 hourly 0.9 https://trial.medpath.com/news/adial-pharmaceuticals-completes-validation-of-genetic-test-for-alcohol-use-disorder-treatment 2025-10-09T17:17:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adial-pharmaceuticals-completes-validation-of-genetic-test-for-alcohol-use-disorder-treatment 2025-10-09T17:17:19+00:00 hourly 0.9 https://trial.medpath.com/news/bd-launches-xtract-registry-to-evaluate-real-world-performance-of-rotarex-catheter-system-in-peripheral-artery-disease 2025-10-09T17:16:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bd-launches-xtract-registry-to-evaluate-real-world-performance-of-rotarex-catheter-system-in-peripheral-artery-disease 2025-10-09T17:16:02+00:00 hourly 0.9 https://trial.medpath.com/news/advances-in-cancer-immunotherapy-reveal-complex-interplay-between-tumor-microenvironment-and-neoantigen-targeting 2025-10-09T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/advances-in-cancer-immunotherapy-reveal-complex-interplay-between-tumor-microenvironment-and-neoantigen-targeting 2025-10-09T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-acquires-akero-therapeutics-for-5-2-billion-to-expand-mash-treatment-portfolio 2025-10-09T13:27:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novo-nordisk-acquires-akero-therapeutics-for-5-2-billion-to-expand-mash-treatment-portfolio 2025-10-09T13:27:17+00:00 hourly 0.9 https://trial.medpath.com/news/zelluna-receives-mhra-approval-for-first-in-human-trial-of-novel-tcr-nk-cell-therapy-zi-ma4-1 2025-10-09T13:26:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zelluna-receives-mhra-approval-for-first-in-human-trial-of-novel-tcr-nk-cell-therapy-zi-ma4-1 2025-10-09T13:26:25+00:00 hourly 0.9 https://trial.medpath.com/news/samsung-biologics-expands-japan-presence-with-new-excellens-brand-secures-half-of-top-10-pharma-companies 2025-10-09T13:25:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/samsung-biologics-expands-japan-presence-with-new-excellens-brand-secures-half-of-top-10-pharma-companies 2025-10-09T13:25:48+00:00 hourly 0.9 https://trial.medpath.com/news/chance-pharma-partners-with-huadong-medicine-for-cxg87-asthma-treatment-in-china 2025-10-09T13:24:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chance-pharma-partners-with-huadong-medicine-for-cxg87-asthma-treatment-in-china 2025-10-09T13:24:02+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-fast-track-designation-to-adcendo-s-adce-d01-for-soft-tissue-sarcoma-treatment 2025-10-09T13:24:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-fast-track-designation-to-adcendo-s-adce-d01-for-soft-tissue-sarcoma-treatment 2025-10-09T13:24:00+00:00 hourly 0.9 https://trial.medpath.com/news/aviadobio-secures-413m-option-deal-for-ugx-202-optogenetics-gene-therapy-to-restore-vision-in-retinitis-pigmentosa 2025-10-09T13:22:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aviadobio-secures-413m-option-deal-for-ugx-202-optogenetics-gene-therapy-to-restore-vision-in-retinitis-pigmentosa 2025-10-09T13:22:40+00:00 hourly 0.9 https://trial.medpath.com/news/university-of-washington-develops-programmable-proteins-with-boolean-logic-for-precision-drug-delivery 2025-10-09T13:21:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/university-of-washington-develops-programmable-proteins-with-boolean-logic-for-precision-drug-delivery 2025-10-09T13:21:20+00:00 hourly 0.9 https://trial.medpath.com/news/zymeworks-appoints-dr-adam-schayowitz-as-acting-chief-development-officer-to-advance-oncology-pipeline 2025-10-09T13:21:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zymeworks-appoints-dr-adam-schayowitz-as-acting-chief-development-officer-to-advance-oncology-pipeline 2025-10-09T13:21:09+00:00 hourly 0.9 https://trial.medpath.com/news/ono-pharmaceutical-reports-promising-phase-2-results-for-ono-2808-in-multiple-system-atrophy-treatment 2025-10-09T13:20:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ono-pharmaceutical-reports-promising-phase-2-results-for-ono-2808-in-multiple-system-atrophy-treatment 2025-10-09T13:20:57+00:00 hourly 0.9 https://trial.medpath.com/news/ono-4578-ep4-antagonist-combination-shows-significant-pfs-improvement-in-advanced-gastric-cancer 2025-10-09T13:19:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ono-4578-ep4-antagonist-combination-shows-significant-pfs-improvement-in-advanced-gastric-cancer 2025-10-09T13:19:42+00:00 hourly 0.9 https://trial.medpath.com/news/ariceum-therapeutics-advances-225ac-sso110-for-extensive-stage-small-cell-lung-cancer-with-novel-radioligand-therapy-approach 2025-10-09T09:19:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ariceum-therapeutics-advances-225ac-sso110-for-extensive-stage-small-cell-lung-cancer-with-novel-radioligand-therapy-approach 2025-10-09T09:19:30+00:00 hourly 0.9 https://trial.medpath.com/news/cutaneous-squamous-cell-carcinoma-pipeline-shows-robust-activity-with-45-therapies-in-development 2025-10-09T09:16:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cutaneous-squamous-cell-carcinoma-pipeline-shows-robust-activity-with-45-therapies-in-development 2025-10-09T09:16:54+00:00 hourly 0.9 https://trial.medpath.com/news/fda-breakthrough-therapy-designation-shows-72-approval-success-rate-in-decade-long-analysis 2025-10-09T09:13:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-breakthrough-therapy-designation-shows-72-approval-success-rate-in-decade-long-analysis 2025-10-09T09:13:54+00:00 hourly 0.9 https://trial.medpath.com/news/vaxart-advances-second-generation-norovirus-oral-vaccine-with-improved-immune-response-data 2025-10-09T05:15:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vaxart-advances-second-generation-norovirus-oral-vaccine-with-improved-immune-response-data 2025-10-09T05:15:25+00:00 hourly 0.9 https://trial.medpath.com/news/phase-3-amplitude-trial-shows-niraparib-abiraterone-combination-improves-outcomes-in-hrr-deficient-metastatic-prostate-cancer 2025-10-09T05:14:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-3-amplitude-trial-shows-niraparib-abiraterone-combination-improves-outcomes-in-hrr-deficient-metastatic-prostate-cancer 2025-10-09T05:14:20+00:00 hourly 0.9 https://trial.medpath.com/news/mirxes-gastroclear-becomes-first-nmpa-approved-blood-test-for-gastric-cancer-screening-in-china 2025-10-09T05:13:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mirxes-gastroclear-becomes-first-nmpa-approved-blood-test-for-gastric-cancer-screening-in-china 2025-10-09T05:13:32+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-lasix-onyu-first-at-home-subcutaneous-diuretic-for-heart-failure-patients 2025-10-09T05:13:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-lasix-onyu-first-at-home-subcutaneous-diuretic-for-heart-failure-patients 2025-10-09T05:13:26+00:00 hourly 0.9 https://trial.medpath.com/news/lisata-therapeutics-partners-with-catalent-for-novel-adc-development-using-certepetide-technology 2025-10-09T01:19:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lisata-therapeutics-partners-with-catalent-for-novel-adc-development-using-certepetide-technology 2025-10-09T01:19:32+00:00 hourly 0.9 https://trial.medpath.com/news/memantine-shows-promise-for-autism-communication-in-children-with-elevated-brain-glutamate 2025-10-09T01:18:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/memantine-shows-promise-for-autism-communication-in-children-with-elevated-brain-glutamate 2025-10-09T01:18:51+00:00 hourly 0.9 https://trial.medpath.com/news/glp-1-agonists-may-interfere-with-cancer-imaging-potentially-leading-to-misdiagnosis 2025-10-09T01:18:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glp-1-agonists-may-interfere-with-cancer-imaging-potentially-leading-to-misdiagnosis 2025-10-09T01:18:38+00:00 hourly 0.9 https://trial.medpath.com/news/covid-19-boosters-reduce-hospitalizations-and-deaths-by-up-to-64-in-large-veterans-study 2025-10-09T01:17:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/covid-19-boosters-reduce-hospitalizations-and-deaths-by-up-to-64-in-large-veterans-study 2025-10-09T01:17:31+00:00 hourly 0.9 https://trial.medpath.com/news/hope-medicine-reports-positive-phase-2-results-for-non-hormonal-endometriosis-treatment-hmi-115 2025-10-09T01:16:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hope-medicine-reports-positive-phase-2-results-for-non-hormonal-endometriosis-treatment-hmi-115 2025-10-09T01:16:46+00:00 hourly 0.9 https://trial.medpath.com/news/arthrosi-raises-153m-to-advance-next-generation-gout-therapy-through-phase-iii-trials 2025-10-09T01:15:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arthrosi-raises-153m-to-advance-next-generation-gout-therapy-through-phase-iii-trials 2025-10-09T01:15:22+00:00 hourly 0.9 https://trial.medpath.com/news/ascendis-pharma-submits-european-marketing-application-for-transcon-cnp-in-achondroplasia-treatment 2025-10-09T01:14:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ascendis-pharma-submits-european-marketing-application-for-transcon-cnp-in-achondroplasia-treatment 2025-10-09T01:14:38+00:00 hourly 0.9 https://trial.medpath.com/news/serial-tumor-biopsies-reveal-hidden-immune-responses-in-glioblastoma-treatment 2025-10-08T21:20:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/serial-tumor-biopsies-reveal-hidden-immune-responses-in-glioblastoma-treatment 2025-10-08T21:20:13+00:00 hourly 0.9 https://trial.medpath.com/news/ucsf-researchers-develop-novel-immunotherapy-combination-to-target-colorectal-cancer-liver-metastases 2025-10-08T21:18:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ucsf-researchers-develop-novel-immunotherapy-combination-to-target-colorectal-cancer-liver-metastases 2025-10-08T21:18:51+00:00 hourly 0.9 https://trial.medpath.com/news/trivalent-salmonella-vaccine-shows-strong-immune-response-in-phase-1-trial 2025-10-08T21:18:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trivalent-salmonella-vaccine-shows-strong-immune-response-in-phase-1-trial 2025-10-08T21:18:04+00:00 hourly 0.9 https://trial.medpath.com/news/aardvark-therapeutics-expands-phase-3-hero-trial-for-prader-willi-syndrome-treatment-to-include-younger-patients 2025-10-08T21:17:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aardvark-therapeutics-expands-phase-3-hero-trial-for-prader-willi-syndrome-treatment-to-include-younger-patients 2025-10-08T21:17:21+00:00 hourly 0.9 https://trial.medpath.com/news/theranica-presents-real-world-evidence-supporting-drug-free-migraine-treatment-at-cns-2025 2025-10-08T21:15:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/theranica-presents-real-world-evidence-supporting-drug-free-migraine-treatment-at-cns-2025 2025-10-08T21:15:55+00:00 hourly 0.9 https://trial.medpath.com/news/zenas-biopharma-acquires-three-autoimmune-drugs-from-innocare-in-2-billion-deal 2025-10-08T21:15:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zenas-biopharma-acquires-three-autoimmune-drugs-from-innocare-in-2-billion-deal 2025-10-08T21:15:27+00:00 hourly 0.9 https://trial.medpath.com/news/fairjourney-biologics-appoints-former-evotec-ceo-werner-lanthaler-to-lead-antibody-discovery-platform 2025-10-08T17:28:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fairjourney-biologics-appoints-former-evotec-ceo-werner-lanthaler-to-lead-antibody-discovery-platform 2025-10-08T17:28:11+00:00 hourly 0.9 https://trial.medpath.com/news/coave-therapeutics-advances-novel-gene-therapy-for-retinal-vascular-diseases-with-superior-suprachoroidal-capsid 2025-10-08T17:26:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/coave-therapeutics-advances-novel-gene-therapy-for-retinal-vascular-diseases-with-superior-suprachoroidal-capsid 2025-10-08T17:26:30+00:00 hourly 0.9 https://trial.medpath.com/news/kiel-laboratories-achieves-16th-fda-approval-with-novel-excipient-based-oral-suspension-for-rheumatic-diseases 2025-10-08T17:26:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kiel-laboratories-achieves-16th-fda-approval-with-novel-excipient-based-oral-suspension-for-rheumatic-diseases 2025-10-08T17:26:03+00:00 hourly 0.9 https://trial.medpath.com/news/lonza-expands-biologics-manufacturing-with-new-gmp-approved-filling-line-in-switzerland 2025-10-08T17:24:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lonza-expands-biologics-manufacturing-with-new-gmp-approved-filling-line-in-switzerland 2025-10-08T17:24:47+00:00 hourly 0.9 https://trial.medpath.com/news/global-standard-for-dengue-treatment-trials-published-to-accelerate-drug-development 2025-10-08T17:24:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-standard-for-dengue-treatment-trials-published-to-accelerate-drug-development 2025-10-08T17:24:42+00:00 hourly 0.9 https://trial.medpath.com/news/gold-nanoparticle-nasal-spray-delivers-targeted-lithium-therapy-to-brain-for-neuropsychiatric-disorders 2025-10-08T17:24:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gold-nanoparticle-nasal-spray-delivers-targeted-lithium-therapy-to-brain-for-neuropsychiatric-disorders 2025-10-08T17:24:09+00:00 hourly 0.9 https://trial.medpath.com/news/ars-pharmaceuticals-secures-european-patent-protection-for-neffy-epinephrine-nasal-spray-through-2039 2025-10-08T17:23:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ars-pharmaceuticals-secures-european-patent-protection-for-neffy-epinephrine-nasal-spray-through-2039 2025-10-08T17:23:48+00:00 hourly 0.9 https://trial.medpath.com/news/nutriband-files-patent-application-to-strengthen-abuse-deterrent-technology-for-opioid-patches 2025-10-08T17:23:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nutriband-files-patent-application-to-strengthen-abuse-deterrent-technology-for-opioid-patches 2025-10-08T17:23:20+00:00 hourly 0.9 https://trial.medpath.com/news/tessera-therapeutics-secures-41-3-million-arpa-h-award-to-develop-revolutionary-in-vivo-car-t-therapy 2025-10-08T17:23:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tessera-therapeutics-secures-41-3-million-arpa-h-award-to-develop-revolutionary-in-vivo-car-t-therapy 2025-10-08T17:23:15+00:00 hourly 0.9 https://trial.medpath.com/news/itm-s-phase-3-compete-trial-dosimetry-data-shows-targeted-tumor-uptake-for-177lu-edotreotide-in-neuroendocrine-tumors 2025-10-08T17:22:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/itm-s-phase-3-compete-trial-dosimetry-data-shows-targeted-tumor-uptake-for-177lu-edotreotide-in-neuroendocrine-tumors 2025-10-08T17:22:21+00:00 hourly 0.9 https://trial.medpath.com/news/rigel-pharmaceuticals-advances-r289-phase-1b-trial-for-lower-risk-mds-with-first-dose-expansion-patient 2025-10-08T17:22:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rigel-pharmaceuticals-advances-r289-phase-1b-trial-for-lower-risk-mds-with-first-dose-expansion-patient 2025-10-08T17:22:02+00:00 hourly 0.9 https://trial.medpath.com/news/boehringer-ingelheim-acquires-first-in-class-oncology-asset-from-accent-therapeutics-targeting-high-isg-expression-tumors 2025-10-08T17:21:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/boehringer-ingelheim-acquires-first-in-class-oncology-asset-from-accent-therapeutics-targeting-high-isg-expression-tumors 2025-10-08T17:21:33+00:00 hourly 0.9 https://trial.medpath.com/news/alpha-fusion-establishes-world-s-first-commercial-at-211-drug-supply-chain-for-thyroid-cancer-trial 2025-10-08T17:21:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alpha-fusion-establishes-world-s-first-commercial-at-211-drug-supply-chain-for-thyroid-cancer-trial 2025-10-08T17:21:22+00:00 hourly 0.9 https://trial.medpath.com/news/fda-authorizes-expanded-access-program-for-first-in-class-tourette-syndrome-drug-ecopipam 2025-10-08T17:21:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-authorizes-expanded-access-program-for-first-in-class-tourette-syndrome-drug-ecopipam 2025-10-08T17:21:11+00:00 hourly 0.9 https://trial.medpath.com/news/ascend-advanced-therapies-successfully-defends-european-patent-for-epyq-aav-plasmid-technology 2025-10-08T17:20:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ascend-advanced-therapies-successfully-defends-european-patent-for-epyq-aav-plasmid-technology 2025-10-08T17:20:57+00:00 hourly 0.9 https://trial.medpath.com/news/bd-and-opentrons-partner-to-automate-single-cell-multiomics-research-for-drug-development 2025-10-08T17:20:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bd-and-opentrons-partner-to-automate-single-cell-multiomics-research-for-drug-development 2025-10-08T17:20:43+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-s-alphamedix-radioligand-therapy-meets-all-primary-endpoints-in-phase-2-gep-net-trial 2025-10-08T17:20:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanofi-s-alphamedix-radioligand-therapy-meets-all-primary-endpoints-in-phase-2-gep-net-trial 2025-10-08T17:20:01+00:00 hourly 0.9 https://trial.medpath.com/news/spruce-biosciences-secures-50m-to-advance-sanfilippo-syndrome-type-b-therapy-toward-bla-submission 2025-10-08T17:19:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/spruce-biosciences-secures-50m-to-advance-sanfilippo-syndrome-type-b-therapy-toward-bla-submission 2025-10-08T17:19:22+00:00 hourly 0.9 https://trial.medpath.com/news/lumen-bioscience-strengthens-leadership-following-30m-series-c-extension-to-advance-oral-biologics-platform 2025-10-08T17:18:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lumen-bioscience-strengthens-leadership-following-30m-series-c-extension-to-advance-oral-biologics-platform 2025-10-08T17:18:48+00:00 hourly 0.9 https://trial.medpath.com/news/sandoz-and-formycon-secure-aflibercept-biosimilar-settlement-agreements-with-regeneron 2025-10-08T17:17:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sandoz-and-formycon-secure-aflibercept-biosimilar-settlement-agreements-with-regeneron 2025-10-08T17:17:00+00:00 hourly 0.9 https://trial.medpath.com/news/zimmer-biomet-and-paragon-28-launch-advanced-foot-and-ankle-trauma-systems-for-complex-fracture-management 2025-10-08T17:16:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zimmer-biomet-and-paragon-28-launch-advanced-foot-and-ankle-trauma-systems-for-complex-fracture-management 2025-10-08T17:16:14+00:00 hourly 0.9 https://trial.medpath.com/news/four-biotech-companies-report-promising-clinical-trial-milestones-across-cancer-hearing-loss-and-rare-disease-treatments 2025-10-08T17:15:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/four-biotech-companies-report-promising-clinical-trial-milestones-across-cancer-hearing-loss-and-rare-disease-treatments 2025-10-08T17:15:41+00:00 hourly 0.9 https://trial.medpath.com/news/science-37-achieves-third-consecutive-fda-nai-inspection-rating-for-direct-to-patient-clinical-trial-platform 2025-10-08T17:14:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/science-37-achieves-third-consecutive-fda-nai-inspection-rating-for-direct-to-patient-clinical-trial-platform 2025-10-08T17:14:37+00:00 hourly 0.9 https://trial.medpath.com/news/ireland-launches-phase-2-of-precision-oncology-ireland-program-with-expanded-investment-and-clinical-focus 2025-10-08T17:14:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ireland-launches-phase-2-of-precision-oncology-ireland-program-with-expanded-investment-and-clinical-focus 2025-10-08T17:14:11+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-celon-pharma-s-novel-pde10a-inhibitor-cpl-936-for-phase-3-schizophrenia-trials 2025-10-08T13:17:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-celon-pharma-s-novel-pde10a-inhibitor-cpl-936-for-phase-3-schizophrenia-trials 2025-10-08T13:17:57+00:00 hourly 0.9 https://trial.medpath.com/news/zenas-biopharma-secures-global-rights-to-orelabrutinib-btk-inhibitor-for-multiple-sclerosis-in-2-billion-deal 2025-10-08T13:17:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zenas-biopharma-secures-global-rights-to-orelabrutinib-btk-inhibitor-for-multiple-sclerosis-in-2-billion-deal 2025-10-08T13:17:54+00:00 hourly 0.9 https://trial.medpath.com/news/phase-1-trial-establishes-bireociclib-as-promising-cdk4-6-inhibitor-for-advanced-breast-cancer-treatment 2025-10-08T13:16:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-1-trial-establishes-bireociclib-as-promising-cdk4-6-inhibitor-for-advanced-breast-cancer-treatment 2025-10-08T13:16:11+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-blood-test-achieves-96-accuracy-in-diagnosing-chronic-fatigue-syndrome 2025-10-08T13:15:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-blood-test-achieves-96-accuracy-in-diagnosing-chronic-fatigue-syndrome 2025-10-08T13:15:45+00:00 hourly 0.9 https://trial.medpath.com/news/three-cdmos-form-integrated-cmc-partnership-to-accelerate-drug-development-from-discovery-to-clinic 2025-10-08T13:15:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/three-cdmos-form-integrated-cmc-partnership-to-accelerate-drug-development-from-discovery-to-clinic 2025-10-08T13:15:43+00:00 hourly 0.9 https://trial.medpath.com/news/phase-3-trial-launches-for-novel-triple-drug-malaria-treatment-to-combat-artemisinin-resistance 2025-10-08T13:15:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-3-trial-launches-for-novel-triple-drug-malaria-treatment-to-combat-artemisinin-resistance 2025-10-08T13:15:20+00:00 hourly 0.9 https://trial.medpath.com/news/nilo-therapeutics-emerges-from-stealth-with-101-million-to-develop-neural-circuit-based-immunomodulation-therapies 2025-10-08T13:15:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nilo-therapeutics-emerges-from-stealth-with-101-million-to-develop-neural-circuit-based-immunomodulation-therapies 2025-10-08T13:15:10+00:00 hourly 0.9 https://trial.medpath.com/news/bbg-advanced-therapies-and-cellforcure-form-transatlantic-partnership-to-expand-atmp-manufacturing-capacity 2025-10-08T09:16:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bbg-advanced-therapies-and-cellforcure-form-transatlantic-partnership-to-expand-atmp-manufacturing-capacity 2025-10-08T09:16:30+00:00 hourly 0.9 https://trial.medpath.com/news/bioinvent-initiates-phase-2a-trial-of-bi-1206-plus-pembrolizumab-for-advanced-nsclc-and-uveal-melanoma 2025-10-08T09:15:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bioinvent-initiates-phase-2a-trial-of-bi-1206-plus-pembrolizumab-for-advanced-nsclc-and-uveal-melanoma 2025-10-08T09:15:44+00:00 hourly 0.9 https://trial.medpath.com/news/dimerix-s-dmx-200-advances-in-phase-3-fsgs-trial-with-strong-safety-profile-and-fda-aligned-endpoint-data 2025-10-08T09:15:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dimerix-s-dmx-200-advances-in-phase-3-fsgs-trial-with-strong-safety-profile-and-fda-aligned-endpoint-data 2025-10-08T09:15:39+00:00 hourly 0.9 https://trial.medpath.com/news/angle-plc-rebrands-as-cellbxhealth-appoints-new-executive-chairman-to-drive-ctc-intelligence-strategy 2025-10-08T09:15:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/angle-plc-rebrands-as-cellbxhealth-appoints-new-executive-chairman-to-drive-ctc-intelligence-strategy 2025-10-08T09:15:13+00:00 hourly 0.9 https://trial.medpath.com/news/transmedics-group-stock-surges-102-following-fda-approval-for-new-organ-care-system 2025-10-08T09:14:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/transmedics-group-stock-surges-102-following-fda-approval-for-new-organ-care-system 2025-10-08T09:14:34+00:00 hourly 0.9 https://trial.medpath.com/news/alphamedix-achieves-all-primary-endpoints-in-phase-2-trial-for-gastroenteropancreatic-neuroendocrine-tumors 2025-10-08T09:14:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alphamedix-achieves-all-primary-endpoints-in-phase-2-trial-for-gastroenteropancreatic-neuroendocrine-tumors 2025-10-08T09:14:08+00:00 hourly 0.9 https://trial.medpath.com/news/celaid-therapeutics-secures-7-2-million-series-b-funding-to-advance-pediatric-stem-cell-therapy-cld-001 2025-10-08T05:16:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/celaid-therapeutics-secures-7-2-million-series-b-funding-to-advance-pediatric-stem-cell-therapy-cld-001 2025-10-08T05:16:07+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-complete-response-letter-for-xspray-pharma-s-dasynoc-citing-manufacturing-issues 2025-10-08T05:14:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-complete-response-letter-for-xspray-pharma-s-dasynoc-citing-manufacturing-issues 2025-10-08T05:14:42+00:00 hourly 0.9 https://trial.medpath.com/news/carsgen-s-gprc5d-car-t-therapy-ct071-achieves-100-response-rate-in-heavily-pretreated-multiple-myeloma-patients 2025-10-08T05:14:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/carsgen-s-gprc5d-car-t-therapy-ct071-achieves-100-response-rate-in-heavily-pretreated-multiple-myeloma-patients 2025-10-08T05:14:34+00:00 hourly 0.9 https://trial.medpath.com/news/painchek-receives-historic-fda-de-novo-approval-for-first-regulated-pain-assessment-device-in-us-market 2025-10-08T05:14:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/painchek-receives-historic-fda-de-novo-approval-for-first-regulated-pain-assessment-device-in-us-market 2025-10-08T05:14:03+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-s-omvoh-demonstrates-sustained-four-year-efficacy-in-ulcerative-colitis-extension-trial 2025-10-08T03:14:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eli-lilly-s-omvoh-demonstrates-sustained-four-year-efficacy-in-ulcerative-colitis-extension-trial 2025-10-08T03:14:33+00:00 hourly 0.9 https://trial.medpath.com/news/major-study-questions-tramadol-s-effectiveness-for-chronic-pain-reveals-increased-cardiac-risk 2025-10-08T01:18:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/major-study-questions-tramadol-s-effectiveness-for-chronic-pain-reveals-increased-cardiac-risk 2025-10-08T01:18:34+00:00 hourly 0.9 https://trial.medpath.com/news/glaukos-corporation-breaks-ground-on-82m-ophthalmic-r-d-facility-in-alabama 2025-10-08T01:17:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glaukos-corporation-breaks-ground-on-82m-ophthalmic-r-d-facility-in-alabama 2025-10-08T01:17:19+00:00 hourly 0.9 https://trial.medpath.com/news/cyteph-completes-enrollment-for-first-in-human-cyt-101-trial-in-recurrent-glioblastoma 2025-10-08T01:16:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cyteph-completes-enrollment-for-first-in-human-cyt-101-trial-in-recurrent-glioblastoma 2025-10-08T01:16:08+00:00 hourly 0.9 https://trial.medpath.com/news/immuron-submits-ind-application-to-fda-for-novel-c-difficile-therapy-imm-529 2025-10-08T01:15:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immuron-submits-ind-application-to-fda-for-novel-c-difficile-therapy-imm-529 2025-10-08T01:15:58+00:00 hourly 0.9 https://trial.medpath.com/news/humacyte-secures-60-million-in-oversubscribed-offering-to-advance-bioengineered-tissue-platform 2025-10-08T01:15:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/humacyte-secures-60-million-in-oversubscribed-offering-to-advance-bioengineered-tissue-platform 2025-10-08T01:15:43+00:00 hourly 0.9 https://trial.medpath.com/news/celonic-and-carbogen-amcis-form-strategic-alliance-for-integrated-adc-development-and-manufacturing 2025-10-08T01:15:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/celonic-and-carbogen-amcis-form-strategic-alliance-for-integrated-adc-development-and-manufacturing 2025-10-08T01:15:30+00:00 hourly 0.9 https://trial.medpath.com/news/zimmer-biomet-completes-177-million-acquisition-of-monogram-technologies-to-pioneer-autonomous-orthopedic-robotics 2025-10-08T01:15:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zimmer-biomet-completes-177-million-acquisition-of-monogram-technologies-to-pioneer-autonomous-orthopedic-robotics 2025-10-08T01:15:27+00:00 hourly 0.9 https://trial.medpath.com/news/hengrui-advances-kras-g12d-inhibitor-hrs-4642-to-phase-3-trial-in-pancreatic-cancer 2025-10-08T01:15:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hengrui-advances-kras-g12d-inhibitor-hrs-4642-to-phase-3-trial-in-pancreatic-cancer 2025-10-08T01:15:22+00:00 hourly 0.9 https://trial.medpath.com/news/verrica-to-present-vp-315-immune-activation-data-from-phase-2-basal-cell-carcinoma-trial-at-sitc-2025 2025-10-08T01:15:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/verrica-to-present-vp-315-immune-activation-data-from-phase-2-basal-cell-carcinoma-trial-at-sitc-2025 2025-10-08T01:15:12+00:00 hourly 0.9 https://trial.medpath.com/news/trudiagnostic-receives-nih-grant-to-develop-revolutionary-epigenetic-disease-prediction-platform 2025-10-08T01:14:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trudiagnostic-receives-nih-grant-to-develop-revolutionary-epigenetic-disease-prediction-platform 2025-10-08T01:14:36+00:00 hourly 0.9 https://trial.medpath.com/news/former-fda-vaccine-chief-peter-marks-joins-eli-lilly-to-lead-infectious-disease-and-molecule-discovery 2025-10-08T01:14:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/former-fda-vaccine-chief-peter-marks-joins-eli-lilly-to-lead-infectious-disease-and-molecule-discovery 2025-10-08T01:14:34+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-johnson-johnson-s-simponi-for-pediatric-ulcerative-colitis-treatment 2025-10-08T01:14:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-johnson-johnson-s-simponi-for-pediatric-ulcerative-colitis-treatment 2025-10-08T01:14:14+00:00 hourly 0.9 https://trial.medpath.com/news/nexalin-s-neurostimulation-device-shows-significant-cognitive-improvements-in-alzheimer-s-disease-trial 2025-10-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nexalin-s-neurostimulation-device-shows-significant-cognitive-improvements-in-alzheimer-s-disease-trial 2025-10-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/uk-pharma-industry-pushes-for-67-increase-in-nice-cost-effectiveness-threshold-amid-investment-exodus 2025-10-07T21:23:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-pharma-industry-pushes-for-67-increase-in-nice-cost-effectiveness-threshold-amid-investment-exodus 2025-10-07T21:23:15+00:00 hourly 0.9 https://trial.medpath.com/news/patent-board-rules-against-johns-hopkins-in-pembrolizumab-patent-dispute-with-merck 2025-10-07T21:19:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/patent-board-rules-against-johns-hopkins-in-pembrolizumab-patent-dispute-with-merck 2025-10-07T21:19:39+00:00 hourly 0.9 https://trial.medpath.com/news/kernal-bio-secures-48-million-arpa-h-grant-to-develop-revolutionary-in-vivo-car-t-cell-therapies 2025-10-07T21:19:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kernal-bio-secures-48-million-arpa-h-grant-to-develop-revolutionary-in-vivo-car-t-cell-therapies 2025-10-07T21:19:08+00:00 hourly 0.9 https://trial.medpath.com/news/jcr-pharmaceuticals-just-aav-platform-achieves-52-fold-improvement-in-muscle-gene-delivery-while-reducing-liver-exposure 2025-10-07T21:18:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jcr-pharmaceuticals-just-aav-platform-achieves-52-fold-improvement-in-muscle-gene-delivery-while-reducing-liver-exposure 2025-10-07T21:18:15+00:00 hourly 0.9 https://trial.medpath.com/news/predicta-biosciences-raises-23-4m-series-a-to-advance-non-invasive-diagnostics-for-multiple-myeloma-and-blood-cancers 2025-10-07T21:17:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/predicta-biosciences-raises-23-4m-series-a-to-advance-non-invasive-diagnostics-for-multiple-myeloma-and-blood-cancers 2025-10-07T21:17:44+00:00 hourly 0.9 https://trial.medpath.com/news/cnd-life-sciences-receives-fda-breakthrough-device-designation-and-3m-nih-grant-for-parkinson-s-disease-diagnostic-test 2025-10-07T21:14:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cnd-life-sciences-receives-fda-breakthrough-device-designation-and-3m-nih-grant-for-parkinson-s-disease-diagnostic-test 2025-10-07T21:14:39+00:00 hourly 0.9 https://trial.medpath.com/news/neurona-therapeutics-receives-ema-prime-designation-for-nrtx-1001-cell-therapy-in-drug-resistant-focal-epilepsy 2025-10-07T20:13:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neurona-therapeutics-receives-ema-prime-designation-for-nrtx-1001-cell-therapy-in-drug-resistant-focal-epilepsy 2025-10-07T20:13:00+00:00 hourly 0.9 https://trial.medpath.com/news/alloy-therapeutics-partners-with-university-of-british-columbia-to-accelerate-pandemic-preparedness-through-cryo-em-antibody-discovery 2025-10-07T17:28:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alloy-therapeutics-partners-with-university-of-british-columbia-to-accelerate-pandemic-preparedness-through-cryo-em-antibody-discovery 2025-10-07T17:28:16+00:00 hourly 0.9 https://trial.medpath.com/news/zoliflodacin-shows-high-cure-rates-against-resistant-gonorrhea-in-phase-3-trial-subset-analysis 2025-10-07T17:24:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zoliflodacin-shows-high-cure-rates-against-resistant-gonorrhea-in-phase-3-trial-subset-analysis 2025-10-07T17:24:02+00:00 hourly 0.9 https://trial.medpath.com/news/novel-inhalable-crizotinib-nanoparticles-show-promise-for-targeted-lung-cancer-treatment 2025-10-07T17:22:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-inhalable-crizotinib-nanoparticles-show-promise-for-targeted-lung-cancer-treatment 2025-10-07T17:22:27+00:00 hourly 0.9 https://trial.medpath.com/news/affinia-therapeutics-raises-40m-series-c-to-advance-first-in-class-gene-therapy-for-bag3-dilated-cardiomyopathy 2025-10-07T17:21:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/affinia-therapeutics-raises-40m-series-c-to-advance-first-in-class-gene-therapy-for-bag3-dilated-cardiomyopathy 2025-10-07T17:21:00+00:00 hourly 0.9 https://trial.medpath.com/news/eyedura-partners-with-singapore-eye-research-institute-for-insulin-based-neurotrophic-keratitis-treatment 2025-10-07T17:19:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eyedura-partners-with-singapore-eye-research-institute-for-insulin-based-neurotrophic-keratitis-treatment 2025-10-07T17:19:45+00:00 hourly 0.9